UNCLASSIFIED

AD NUMBER ADB285859 **NEW LIMITATION CHANGE** TO Approved for public release, distribution unlimited **FROM** Distribution authorized to U.S. Gov't. agencies only; Proprietary Info.; Oct 2002. Other requests shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott St., Ft. Detrick, MD 21702-5012. **AUTHORITY** USAMRMC ltr, 18 Apr 2003

AD)			

Award Number: DAMD17-00-2-0065

TITLE: Non-Invasive Ultrasonic Diagnosing and Monitoring of

Intracranial Pressure/Volume

PRINCIPAL INVESTIGATOR: Aloyzas Petrikas, Ph.D.

Arminas Ragauskas Gediminas Daubaris

CONTRACTING ORGANIZATION: Vitta Corporation

Bethel, Connecticut 06801

REPORT DATE: October 2002

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command

Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Distribution authorized to U.S. Government agencies only (proprietary information, Oct 02). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, Maryland 21702-5012.

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

NOTICE

USING GOVERNMENT DRAWINGS, SPECIFICATIONS, OR OTHER DATA INCLUDED IN THIS DOCUMENT FOR ANY PURPOSE OTHER PROCUREMENT DOES NOT IN ANY WAY THAN GOVERNMENT FACT THAT THE OBLIGATE THE U.S. GOVERNMENT. THEFORMULATED SUPPLIED THE GOVERNMENT OR DRAWINGS, SPECIFICATIONS, OR OTHER DATA DOES NOT LICENSE HOLDER OR ANY OTHER PERSON OR CORPORATION; OR CONVEY ANY RIGHTS OR PERMISSION TO MANUFACTURE, USE, OR SELL ANY PATENTED INVENTION THAT MAY RELATE TO THEM.

LIMITED RIGHTS LEGEND

Award Number: DAMD17-00-2-0065 Organization: Vitta Corporation

Those portions of the technical data contained in this report marked as limited rights data shall not, without the written permission of the above contractor, be (a) released or disclosed outside the government, (b) used by the Government for manufacture or, in the case of computer software documentation, for preparing the same or similar computer software, or (c) used by a party other than the Government, except that the Government may release or disclose technical data to persons outside the Government, or permit the use of technical data by such persons, if (i) such release, disclosure, or use is necessary for emergency repair or overhaul or (ii) is a release or disclosure of technical data (other than detailed manufacturing or process data) to, or use of such data by, a foreign government that is in the interest of the Government and is required for evaluational or informational purposes, provided in either case that such release, disclosure or use is made subject to a prohibition that the person to whom the data is released or disclosed may not further use, release or disclose such data, and the contractor or subcontractor or subcontractor asserting the restriction is notified of such release, disclosure or use. This legend, together with the indications of the portions of this data which are subject to such limitations, shall be included on any reproduction hereof which includes any part of the portions subject to such limitations.

THIS TECHNICAL REPORT HAS BEEN REVIEWED AND IS APPROVED FOR PUBLICATION.

Coi Geoff Ling	
$\mathcal O$	

REPORT DOCUMENTATION PAGE

Form Approved OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)	2. REPORT DATE	3. REPORT TYPE AND DATES COVERED			
	October 2002	Final (1 Oct 0			
4. TITLE AND SUBTITLE			5. FUNDING N		
Non-Invasive Ultrasonic Diagnosing and Monitoring of			DAMD17-00	-2-0065	
Intracranial Pressure/Vo	olume				
6. AUTHOR(S)					
Aloyzas Petrikas, Ph	.D.				
Arminas Ragauskas					
Gediminas Daubaris					
			0 757507111	0.0004117471011	
7. PERFORMING ORGANIZATION NAM	IE(S) AND ADDRESS(ES)		REPORT NU	G ORGANIZATION	
Vitta Corporation			1121 0111 110		
<u> </u>	0.0001				
Bethel, Connecticut	06801				
E-Mail: apetrikas@vitta	COM				
9. SPONSORING / MONITORING AGE	NCY NAME(S) AND ADDRESS(ES)		NG / MONITORING REPORT NUMBER	
U.S. Army Medical Resear	ah and Material Comma	m d	AGENCIF	REPORT NOWBER	
Fort Detrick, Maryland		.na			
Fort Detrick, Maryland	21/02-5012				
11. SUPPLEMENTARY NOTES					
Report contains color.					
12a. DISTRIBUTION / AVAILABILITY S	TATEMENT			12b. DISTRIBUTION CODE	
Distribution authorized to U.S. Government agencies only (proprieta					
information, Oct 02). Other requests for this document shall be re					
U.S. Army Medical Research and Materiel Command, 504 Scott Street,			Fort		
Detrick, Maryland 21702-50	012.				
13 ARSTRACT (Maximum 200 Words	1			t	

Objectives were to verify the innovative concepts of non-invasive intracranial pressure (ICP) absolute value measurement and noninvasive cerebrovascular autoregulation (CA) continuous monitoring, to prove the design concepts and to perform the limited clinical trials of the new prototype devices. These devices were designed and successfully tested.

Slow intracranial and ABP wave correlation methodology was used for continuous CA invasive and non-invasive monitoring. Prototype of non-invasive CA monitor has been used together with invasive ICP and ABP slow wave monitors in the ICU. 13 patients with traumatic brain injuries were monitored and simultaneous 87 hour monitoring data were analyzed. Also a prototype of ultrasonographic absolute ICP meter was applied for non-invasive ICP measurements on 10 ICU patients following Clinical Research Protocol No.99124006, AIBS No.990135, HSSRB log No.A-9676. 57 simultaneous invasive and non-invasive absolute ICP measurements have been performed.

It has been shown experimentally under ICU conditions that non-invasive CA monitoring reflects the same CA dynamics as an invasive autoregulation monitoring. The hypothesis on the coincidence of invasive and non-invasive CA monitoring results was accepted. This conclusion is based on statistically significant clinical data of this research.

The results of non-invasive absolute ICP measurement method clinical assessment show that this is the only method for non-invasive ICP measurement without the problem of individual calibration of system "patient - non-invasive ICP meter". The hypothesis on zero value of differences between invasive and non-invasive absolute ICP measurements under comparison was accepted after analysis of statistically significant clinical data of this research.

14. SUBJECT TERMS Non-invasive physiolog	15. NUMBER OF PAGES 133		
cerebrovascular autore	16. PRICE CODE		
17. SECURITY CLASSIFICATION OF REPORT	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT
Unclassified	Unlimited		

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89) Prescribed by ANSI Std. Z39-18

TABLE OF CONTENTS

SF 298
TABLE OF CONTENTS
INTRODUCTION
BODY
1.0. NON-INVASIVE ABSOLUTE ICP MEASUREMENT THROUGH THE HUMAN EYE
1.1. BACKGROUND OF NON-INVASIVE ABSOLUTE ICP MEASUREMENT
1.2. NUMERICAL SIMULATION OF ABSOLUTE ICP VALUE MEASUREMENT TECHNOLOGY (VITTAMED)
1.3. CLINICAL STUDY OF NON-INVASIVE ABSOLUTE ICP MEASUREMENT DEVICE
1.3.1. CLINICAL RESEARCH OBJECTIVES
1.3.2. EXPECTED STUDY POPULATION
1.3.3. DECLARATION OF A SPECIFIC NUMBER OF SUBJECTS FOR SAMPLE SIZE10
1.3.4. SPECIFICATION OF THE STATISTICAL POWER ANALYSIS11
1.3.5. THE CLINICAL DATA ANALYSIS PLAN
1.3.6. CLINICAL DATA OF SIMULTANEOUS INVASIVE AND NON-INVASIVE ABSOLUTE ICP MEASUREMENTS
1.4. STATISTICAL TESTING OF THE HYPOTHESIS ON ZERO VALUE OF DIFFERENCES BETWEEN INVASIVE AND NON-INVASIVE ICP MEASUREMENTS
1.4.1. TESTING THE HYPOTHESIS18
1.4.2. CONCLUSION OF CLINICAL STUDY
1.5. TECHNOLOGICAL REQUIREMENTS FOR NON-INVASIVE ABSOLUTE ICP METER PROTOTYPE DEVELOPMENT
2.0. NON-INVASIVE ICP / VOLUME REAL-TIME MONITORING ASSESSMENT IN ICU21
2.1. BACKGROUND
2.2. CLINICAL STUDY OF NON-INVASIVE CONTINUOUS SLOW INTRACRANIAL BLOOD VOLUME WAVES MONITORING AND CEREBROVASCULAR AUTOREGULATION STATE MONITORING
2.2.1. CLINICAL RESEARCH OBJECTIVES21
2.2.2. EXPECTED STUDY POPULATION21
2.2.3. CLINICAL DATA OF NON-INVASIVE CONTINUOUS SLOW INTRACRANIAL BLOOD VOLUME WAVES MONITORING AND CEREBROVASCULAR AUTOREGULATION STATE MONITORING
2.2.4. STATISTICAL EVALUATION OF THE CLINICAL DATA22
2.2.5. ANALYSIS OF CLINICAL DATA

2.2.6. CONCLUSION OF CLINICAL STUDY	30
2.3. TECHNOLOGICAL REQUIREMENTS FOR NON-INVASIVE CEREBROVASCULAR AUTOREGULATION MONITOR PROTOTYPE DEVELOPMENT	30
3. KEY RESEARCH ACCOMPLISHMENTS	32
4. REPORTABLE OUTCOMES	33
5. CONCLUSIONS	34
6. REFERENCES	35
APPENDIXES	37
APPENDIX A	38
CLINICAL RESULTS OF NON-INVASIVE ABSOLUTE INTRACRANIAL PRESSURE MEASUREMENT	38
APPENDIX B	58
CLINICAL RESULTS OF SIMULTANEOUS INVASIVE SLOW INTRACRANIAL PRESSURE . NON-INVASIVE SLOW INTRACRANIAL BLOOD VOLUME WAVES MEASUREMENT	
APPENDIX C	103
CLINICAL RESULTS OF SIMULTANEOUS INVASIVE AND NON-INVASIVE CEREBROVAS AUTOREGULATION STATE MONITORING	
APPENDIX D	131
ATACCC 2001, FORT WALTON BEACH (ABSTRACT OF ORAL PRESENTATION)	131
ATACCC 2002, FORT SANT PETE BEACH (ABSTRACT OF ORAL PRESENTATION)	131

INTRODUCTION

The key objectives of the study were to verify the innovative concepts of non-invasive intracranial pressure (ICP) absolute value measurement and non-invasive cerebrovascular autoregulation (CA) continuous monitoring, to prove the design concepts and to perform the limited clinical trials of the new prototype devices. These devices were designed and successfully tested. The technological requirements for future development of deliverable prototype devices have been defined.

The first-year research accomplishment of this project was presented in our Annual Report (Project Title: Non-invasive Ultrasonic Diagnosing and Monitoring of Intracranial Pressure / Volume) covering the award performance period Oct 1, 2000 – Oct 1, 2001. Our previous Annual Report will be cited in this Final Report as "our Annual Report, 2001".

The key research accomplishment of the award performance period Oct 1, 2001 – Oct 1, 2002 was a clinical study of our non-invasive prototype devices on ICU patients with traumatic brain injuries.

Slow intracranial and ABP wave correlation methodology was used for continuous CA invasive and non-invasive monitoring. A prototype of non-invasive CA monitor has been used together with invasive ICP and ABP slow wave monitors in the ICU.

13 patients with traumatic brain injuries were monitored and 87 hours of simultaneous monitoring data were analyzed. Also a prototype of ultrasonographic non-invasive absolute ICP meter was used for non-invasive ICP measurements on 10 ICU patients following Clinical Research Protocol No.99124006, AIBS No.990135, HSSRB log No.A-9676.

57 simultaneous invasive and non-invasive absolute ICP measurements have been performed in ICU.

It has been shown experimentally under ICU conditions that non-invasive CA monitoring reflects the same CA dynamics as an invasive autoregulation monitoring. The hypothesis on the coincidence of invasive and non-invasive CA monitoring results was accepted after the statistical analysis of clinical data. This conclusion is based on statistically significant clinical data of this research.

The results of clinical assessment of a non-invasive absolute ICP measurement method show that this is the only method for non-invasive ICP measurement without the problem of individual calibration of the system "patient – non-invasive ICP meter". The hypothesis on zero value of differences between invasive and non-invasive absolute ICP measurements under comparison was accepted after the analysis of statistically significant clinical data of this research.

BODY

1.0. NON-INVASIVE ABSOLUTE ICP MEASUREMENT THROUGH THE HUMAN EYE

1.1. Background of non-invasive absolute ICP measurement

Neurological dysfunction resulting from brain injury is associated with a high mortality rate [1,2,3,4,6,7]. The economic burden of the injuries is also large [3]. Aspects of practical importance include an early detection of brain injury, an accurate quantification of the degree of the injury, and a reliable prediction of recovery outcome. Other diagnostic approaches are available to detect and assess brain injuries such as near infrared spectroscopy and cerebral blood velocity or flow using a laser Doppler flow meter or transcranial Doppler blood velocity meter. This project will investigate an innovative ultrasonic technology together with the method of ICP absolute value measurement through the human eye for the combat casualty care application.

Several experimental and clinical studies [4] verified the pathophysiological parameters such as cerebral blood flow (CBF) and ICP which can be employed to describe and assess the individual time course immediately following the brain injury. Non-invasive measurement of the ICP absolute value is extremely important for the early diagnosing of the brain injury in emergency cases before CT and MRI diagnosing, for military and aerospace medicine, for monitoring during transplantological procedures, etc [8-11]. It is expected that the non-invasive ICP technology developed here could provide a solution to some of the problems associated with the current invasive ICP monitoring. The problems include the increased risk of infection, limitations of invasive ICP monitoring duration, delays in obtaining ICP diagnosis in emergency due to the need of implanting the sensors.

1.2. Numerical simulation of absolute ICP value measurement technology (Vittamed)

The purpose of numerical simulation was to analyze the possible systematic error of the proposed non-invasive absolute ICP measurement method and to show that this method does not need the individual calibration of the system "individual patient – non-invasive ICP meter".

The mathematical model of blood flow in the eye artery is based on one-dimensional equations resulting from the Navier-Stokes equations (pulsatile incompressible flow in a flexible tube).

The blood flow in the eye artery mainly depends on the perfusion pressure, the artery diameter and hydrodynamic resistance in the eye microvessels.

The diameter of the eye artery depends on:

- elastic properties of the artery wall,
- elastic properties of the surrounding tissues,
- arterial blood pressure (ABP), ICP and external pressure Pe.

The mathematical model of numerical simulation of pulsating blood flow through the eye artery is based on the assumptions that the behaviour of eye artery and blood flow is axis-symmetric and that arterial pressure is constant across the artery. Therefore, blood flow can be modelled by one-dimensional equations resulting from the integration of three-dimensional non-compressible Navier-Stokes equations over the cross section of the artery. The artery is considered as an axis-symmetric elastic tube. As a result, time evolution of blood volume yield in the artery is described by a system of continuity and momentum equations as follows

$$\frac{\partial A}{\partial t} + \frac{\partial Q}{\partial z} = 0 \tag{1}$$

$$\frac{\partial Q}{\partial t} = -\frac{A}{\rho} \frac{\partial p}{\partial z} - \frac{8\pi\mu}{\rho A} Q - \frac{\partial}{\partial z} \left(\frac{Q^2}{A}\right) \tag{2}$$

where t is time, z is measured along the artery, A(z,t) is the inner cross-section area of the artery, Q(z,t) is the blood volume yield, p(z,t) is an arterial blood pressure, μ and ρ are the blood viscosity and density, respectively.

The system is completed by the equilibrium equation of forces acting on the arterial wall:

$$p - p_{outer} = M \frac{\partial^2 r}{\partial t^2} + \gamma \frac{\partial r}{\partial t} + p_{elastic} + T \frac{\partial^2 r}{\partial z^2}$$
(3)

where r(z,t) is the inner radius of the artery, p_{outer} – pressure acting on the outer wall of the artery and is a function of z, M is related to the density of the the wall, T(r,z) – longitudinal tensile force, γ is the damping coefficient for wall motion, $p_{elastic}$ is pressure created by the elastic force of the arterial wall and is defined as follows

$$p_{elastic} = p_0 \exp\left(k \frac{A - A_0}{A_0}\right) \tag{4}$$

where r_0 is the artery inner radius, while arterial pressure is p_0 and k(z) is arterial stiffness.

The simulation area is divided into three zones: itracranial (inside the brain), inside the cranial canal, and extracranial, what defines different outer pressure: p_{outer} is equal to ICP inside the brain and p_{outer} is equal to the external pressure applied to the eye in the extracranial segment of the eye artery. Under assumption that the eye artery does not pulsate inside the cranial canal, the inner radius of the artery inside the cranial canal is constant. As a result, the equilibrium equation (3) is not solved inside the cranial canal. All zones are coupled during calculations.

Boundary conditions are defined by inlet pressure $p_{in}(t)$ or blood yield $Q_{in}(t)$. As for example, an input yield $Q_{in}(t)$ is approximated by the function displayed in Fig. 1, which is close by the shape to the arterial blood pressure pulse. Results of numerical simulation of absolute ICP value measurement are presented in Fig. 2 - Fig.4.




Fig. 1. Inlet blood volume yield of the eye artery




Fig. 2. Numerical simulation of the relationships between pulsatility indexes PI in the intracranial and extracranial segments of the eye artery on extracranial pressure Pe applied to the eye: when absolute ICP value was equal to 10 mmHg, the balance between intracranial and extracranial PI values was obtained at the point Pe=12.5 mmHg





Fig. 3. Numerical simulation of the relationships between pulsatility indexes PI in the intracranial and extracranial segments of the eye artery on extracranial pressure Pe applied to the eye: when absolute ICP value was equal to 20 mmHg, the balance between intracranial and extracranial PI values was obtained at the point Pe=21 mmHg






Fig. 4. Relationships between the differences of intracranial PI and extracranial PI depending on Pe and ICP: a) numerical model with constant mean blood flow in the eye artery, b) numerical model with Pe dependent mean blood flow in the eye artery

It is shown on Fig. 4 a) and b) that the ICP dependent systematic error of the proposed non-invasive method is within limits from -3 mmHg to +1 mmHg when the absolute ICP values are from ICP=10 mmHg to ICP=40 mmHg. This absolute systematic error is small enough and it is not important in clinical practice.

Results of numerical simulation of non-invasive absolute ICP measurement show the possibility to measure absolute ICP value without the necessity to eliminate such a small systematic error of the proposed method. This result shows that this is only method which does not need the calibration of the system "individual patient – non-invasive ICP meter" because of clinically non-significant absolute ICP measurement errors in the ICP range from 0 mmHg up to 40 mmHg, i.e., below and above the critical ICP threshold 20 ... 25 mmHg.

1.3. Clinical study of non-invasive absolute ICP measurement device

1.3.1. Clinical research objectives

(Clinical Research Protocol No.99124006, AIBS No.990135, HSSRB log No.A-9676):

To conduct a clinical trial on intensive care unit coma patients with heads injuries and implanted existing standard invasive intracranial pressure (ICP) transducers connected to standard ICP monitors, applying simultaneously multidepth transcranial Doppler (TCD) measurements of the eye artery blood flow parameters in the intracranial and extracranial segments of that artery in the case of ICP equal to the external pressure applied to the eye.

1.3.2. Expected study population

(Clinical Research Protocol No.99124006, AIBS No.990135, HSSRB log No.A-9676):

• Male and female subjects >18 years of age with traumatic brain injury.

We intended to study 10 patients with traumatic brain injury. Inclusion criteria: age >=18 years, brain injured patients monitored in an intensive care unit who have invasive arterial and intracranial pressure monitoring. Indications for intracranial pressure monitoring are appropriate in patients with severe head injury with abnormal admission CT scan. Severe head injury is defined as a Glasgow Coma Scale Score of 3-8 after cardiopulmonary resuscitation. An abnormal CT scan of the head is one that reveals hematomas, contusions, edema, or compressed basal cisterns. ICP monitoring is appropriate in patients with severe head injury with a normal CT scan if two or more of the following features are noted at admission: age over 40 years,

unilateral or bilateral motor posturing, systolic blood pressure less than 90 mmHg. ICP monitoring is not routinely indicated in patients with mild or moderate head injury (Guidelines for the Management of Severe Head Injury. Brain Trauma Foundation, USA, 1995). Following the Guidelines for the Management of Severe Head Injury, only comatose patients of ICU with implanted invasive ICP monitoring transducers will be involved in the study.

 Post Sub-arachnoid haemorrhage patients monitored in an intensive care unit who have invasive arterial and intracranial pressure monitoring. Exclusion criteria: patients with wounds, scars or a craniotomy overlying the optimal window for transintracranial ultrasonic measurement.

1.3.3. Declaration of a specific number of subjects for sample size

The goal of the experimental tests is the evaluation of the reliability of data obtained using new non-invasive intracranial pressure measurement methods in comparison with the invasively measured data using an intracranial pressure monitor.

The proposed non-invasive intracranial pressure measurement method does not influence the physiological state of the patient. From the methodological point of view the object of investigation is not the individual patient but the physical parameter (intracranial pressure measured by two ways - invasively and non-invasively), reflecting the dynamics of the physiological state of an individual patient. Therefore, a separate patient can be repeatedly exploited to obtain the required statistics of sample data. The parameter values during measurement tests must cover the entire range of the parameter variation under various physiological states of patients.

The sample data is obtained during a separate measurement cycle of 1 hour duration at which the parallel measurement data from the investigated measurement device and the standard measurement device are registered. In this way, up to 180 000 parallel measurement points are obtained at each measurement cycle. For the data obtained, the Student's distribution statistics test for paired or correlated samples [13] with the significance level 5% is applied to evaluate a coincidence of the measurement results. Therefore, for each measurement cycle a decision is stated (to accept or reject the hypothesis on the coincidence of results).

The consistency of the decisions is to be tested for repeated measurement cycles under various physiological states of patients. The number of measurement cycles is calculated using a general formula for the significance test of a single proportion [14]:

$$n > \frac{\left[u\sqrt{\pi(1-\pi)} + v\sqrt{\pi_0(1-\pi_0)}\right]^2}{(\pi-\pi_0)^2},$$
(1)

where

n - required minimum size of measurement cycles;

 π - proportion of interest;

 π_0 - null hypothesis proportion;

 $\it u$ - one-sided percentage point of the normal distribution corresponding to 100% - $\it power$;

 ${\cal V}$ - percentage of the normal distribution corresponding to the required (two-sided) significance level.

For our investigation we have introduced the following values of the formula (1) parameters:

For our investigation we have introduced the following values of the formula (1) parameters: the proportion of interest $\pi=0.95$; the null hypothesis (measurement results by the investigated and standard methods coincide) proportion $\pi_0=1$; the power value for demonstrating the significant difference between results of measurement cycles is accepted power=95%, which corresponds u=1.645; the significance level is accepted 5%, which corresponds v=1.96.

With the above parameter values, the following value of the required measurement cycles is calculated:

$$n > \frac{\left[1.645\sqrt{0.95(1-0.95)} + 1.96\sqrt{1(1-1)}\right]^2}{(0.95-1)^2} = 52$$
(2)

Under specific experimental conditions, a separate patient can be tested 2 times per day during 5 days. Therefore, the maximum 10 measurement cycles can be obtained from one patient, and the minimum number of patients to obtain the required statistics of samples is

whole number
$$\left(\frac{52}{10}\right) = 6$$
 (patients). (3)

The real number of measurement cycles obtained from one patient, however, can be less than 10 (in practice it varies from 1 to 10), if the physiological state of the patient does not change and the repeated measurement cycles are not informative. The criteria of change are: the state of blood flow autoregulation is changed, or CPP, ABP or ICP values are significantly changed, or B waves became active.

Taking into account the above circumstances, we have increased the calculated value to 10 patients in order to ensure the required statistics of samples under unfavourable experimental conditions.

1.3.4. Specification of the statistical power analysis

As it has been demonstrated by the calculation presented above, the statistics of informative number of measurement cycles N > 52 provides the required power of conclusions. The number of subjects to obtain the required statistics of samples is determined to be 10.

Assuming an idealistic case, if the maximum number of informative samples (10) is obtained from each patient, the whole number of samples available for statistical analysis is $10 \times 10 = 100$. This number significantly exceeds the required minimum value (N > 52). Thus, experimental data available from 10 patients provide a significant reserve for obtaining the required statistics of informative samples, taking into account that the real number of informative samples obtained from a separate patient can be less then 10.

A more exact statistical calculation of the required number of subjects can not be performed, as there is no *a priori* information about statistical distribution of the numbers of informative samples obtained from one patient.

Referring to the above reasoning, we have determined the number 10 of subjects as a

definitive number for obtaining the required statistics of samples.

Under extremely unfavorable conditions of experimental tests, if the minimum number (N > 52) of informative samples were not obtained from 10 patients, the experimental research will be extended by introducing extra patients until the required number of informative samples is obtained.

1.3.5. The clinical data analysis plan

1. Processing the measurement cycles of experimental data in order to evaluate for each measurement cycle a coincidence of measurement data from the investigated measurement device and the standard measurement device.

Calculation is based on the paired data of parallel measurements

$$(x_{inv})_{i}, (x_{st})_{i}, i = 1, ..., n,$$
 (4)

where $(x_{inv})_i$ is the measured value by the investigated device; $(x_{st})_i$ is the measured value by the standard device; i is the index of measurement point; and n is the number of measurement points (up to 180 000).

For each measurement point a difference is calculated:

$$D_{i} = (x_{inv})_{i} - (x_{st})_{i}, \quad i = 1, ..., n$$
(5)

Testing the hypothesis on the equality of the population means is based on the calculated value of the t-test statistics [12]:

$$T = \frac{m_D - 0}{\frac{s}{\sqrt{n}}},\tag{6}$$

which is distributed as Student's t with n-1 degrees of freedom.

Parameters m_D (mean) and S (standard deviation) are calculated using formulas:

$$m_D = \frac{1}{n} \sum_{i=1}^{n} D_i \,, \tag{7}$$

$$s = \sqrt{\frac{1}{n-1} \sum_{i=1}^{n} (D_i - m_D)^2} . \tag{8}$$

The calculated value T is compared with the critical value t, obtained from the statistical table of t-distribution values for the n-1 degrees of freedom and 5% significance level.

If |T| < t, the hypothesis on the equality of the population means is accepted, otherwise the hypothesis is rejected.

In this way, for each measurement cycle a decision is stated: accept or reject the hypothesis on the coincidence of results.

2. Statistical analysis of the results of the informative measurement cycle tests in order to evaluate a coincidence of measurement results for the entire population of samples.

For the investigated number N of informative samples (N>52), a proportion π_{N+} of samples (N_+) with the positive decision on the coincidence of measurement results is calculated:

$$\pi_{N+} = N_+/N \,. \tag{9}$$

The calculated value π_{n+} is compared with the proportion of interest $\pi = 0.95$.

If $\pi_{N+} > \pi$, the hypothesis on the coincidence of measurement results is accepted. Otherwise the hypothesis is rejected.

1.3.6. Clinical data of simultaneous invasive and non-invasive absolute ICP measurements

A clinical study of absolute ICP value measurement technique (two-depth TCD technology) has been performed in order to evaluate a coincidence of invasive and non-invasive empirical results.

ICP absolute value measurement through the human eye is based on the simultaneous ultrasonic measurement of the blood flow parameters in the intracranial and the extracranial segments of the eye artery (see our Annual Report from Sept 2001, pp. 21-24).

We found experimentally that the eye artery behaves passively to an applied transmural pressure. Blood flow velocity pulsations depend on ICP in the intracranial segment and depend on extracranial pressure (Pe) in the extracranial segment.

We also found experimentally that in the case of balance between ICP and Pe, when ICP = Pe, the same blood flow parameters – diastolic, systolic and mean values, pulsatility and resistivity indexes, etc., are approximately equal in the intracranial and extracranial segments of the eye artery. This balance does not depend on the individual anatomy of eye arteries or the eye arterial pressure and the hydrodynamic resistance of the eye artery hydrodynamic load.

The state of balance when ICP = Pe can be achieved by applying external pressure to the eye ball and surrounding tissues by means of a pneumatic camera. The state of balance is identified by measuring the blood velocity parameters of the eye artery through the application of the transcranial Doppler (TCD) multi-depth technique.

We performed a clinical study of our non-invasive absolute ICP measurement technique on 10 ICU patients with traumatic brain injuries (USAMRAA Award No: DAMD17-00-2-0065, Clinical Research Protocol No. 99124006). Invasive and non-invasive absolute ICP measurements were performed simultaneously in different pathophysiological states of the ventilated patients in coma below and above the critical level of ICP = 20...25 mmHg. Here Pe is an external pressure applied to the tissues surrounding the eyeball. The study population is presented in Table 1.

We applied a specially designed two-depth TCD device with a special ultrasonic transducer and the pressure chamber for application of extracranial pressure Pe to the tissues surrounding the eyeball for non-invasive absolute ICP measurements. Codman device "ICP Express" was used for simultaneous invasive absolute ICP measurements (see our Annual Report from Sept 2001,

Table 1. Non-invasive absolute ICP measurement study: ICU patient population

Total	10
Gender: male	10
Age: Mean / Range	27.6/(18-70) years
Pathology: Closed severe traumatic brain injury	100 %
Simultaneous invasive and non-invasive absolute ICP	57 sessions
measurement in ICU	

Some typical dependences of averaged pulsatility indexes PI of the eye artery blood flow in the intracranial and extracranial segments on extracranial pressure Pe are shown in Fig. 5-8. The results of simultaneous ICP measurements are presented in Fig. 9, Fig. 10 and Table 2. The results of all 57 simultaneous invasive and non-invasive measurements on 10 ICU patients are presented in Appendix A.




Fig. 5. Non-invasive measurement of absolute ICP value: invasive ICP=5 mmHg, non-invasive ICP=3 mmHg. d – depth from the surface of the eye lid: d = 44 mm for the extracranial segment and d = 56 mm for the intracranial segment of the eye artery




Fig. 6. Non-invasive measurement of absolute ICP value: invasive ICP=14 mmHg, non-invasive ICP=16 mmHg. d – depth from the surface of the eye lid: d = 42 mm for the extracranial segment and d = 56 mm for the intracranial segment of the eye artery




Fig. 7. Non-invasive measurement of absolute ICP value: invasive ICP=24 mmHg, non-invasive ICP=26 mmHg. d – depth from the surface of the eye lid: d = 44 mm for the extracranial segment and d = 56 mm for the intracranial segment of the eye artery




Fig. 8. Non-invasive measurement of absolute ICP value: invasive ICP=24 mmHg, non-invasive ICP=26 mmHg. d – depth from the surface of the eye lid: d = 40 mm for the extracranial segment and d = 54 mm for the intracranial segment of the eye artery




Fig. 9. Distribution $p(\Delta)$ of the difference between simultaneous invasive and non-invasive ICP measurements: mean μ =0.939 mmHg, standard deviation SD=6.18 mmHg




Fig. 10. Bland Altman plot of simultaneous invasive and non-invasive ICP measurements (10 patients with severe traumatic brain injuries, 57 simultaneous invasive and non-invasive measurements): red line – systematic error trend

Table 2. Invasive and non-invasive ICP measurements data

			P measurements of
ID			Non-invasive ICP, mmHg
No.1, "sl"	11	8.5	11.5
	2	16	16
	3	14	18
	4	6	6
No.2, "dj"	5	8	19
	6	12	14.5
	7	14	12
	8	16	16.5
	9	10	6
	10	5	16
No.3 "rm"	11	8	19.5
	12	10	11.5
	13	6	13
	14	4	2
No.4, "gl"	15	6	3
No.5, "od"	16	24	34
	17	20	6
<u></u>	18	18	17
	19	16	9
	20	14	15
No. 6, "ri"	21	11	8
	22	13	14
	23	15	8
	24	8	2
	25	12 7	19
	26		5
No. 7 1111	27	9	13
No. 7, "zp"	28	15	12
	29	10	3
	30	12	6
	31	5	5
	32	8	0.5
	33	11	1
	34	7	11
	35	9	12
	36	5	3
	37	24	14
	38	26	32
	39	29	27
No. 8, "gs"	40	14	16
	41	16	19
	42	18	12
	43	22	31
No. 9, "ed"	44	24	17
	45	20	15
	46	23	10
	47	27	24
	48	30	26
	49	26	24
	50	21	22
	51	33	43
No. 10, "al"	52	18	10
10. 10, 41	53	20	20
	53	20	26
	55		10
		22	
	56	19	13
	57	16	12

We were able to prove clinically for the first time that our non-invasive absolute ICP meter (Vittamed) is a non-invasive ICP meter which does not need an individual calibration of the system "individual patient – non-invasive ICP meter" because of clinically not significant systematic error of non-invasive measurements μ =0.939 mmHg (Fig. 10).

It is necessary to underline that clinically non-significant systematic error of absolute ICP measurement is achieved without calibration of our non-invasive ICP meter as it was predicted by mathematical modeling and our preliminary experiments.

The other attempts [14] to create the methods for ICP non-invasive measurements are based on some relationships between physical properties of some craniospinal or intracraniospinal biophysical objects (diameter of skull, resonance frequency of skull, thickness of dura mater, thickness of subarachnoid layer, resonance frequency of the pulsation of cerebral ventricles, tissue resonance frequency, pulsatility index of blood flow in cerebral arteries, etc., etc.) and absolute ICP. These relationships depend on a lot of influential factors including arterial blood pressure, cerebrovascular autoregulation state, the pathophysiological state of patients, etc. Such relationships are time-variable and need to be identified periodically. The only way of identification is to apply the periodical calibration of the system "individual patient – noninvasive ICP meter". In order to calibrate such a system it is necessary to apply a non-existing non-invasive absolute ICP meter with better accuracy than a non-invasive ICP meter under calibration. This situation is a paradox because such an accurate non-invasive absolute ICP calibrator still does not exist. Because of that the only solution of the problem is to measure absolute ICP non-invasively by applying the "Vittamed" non-invasive meter which is the only meter without the problem of calibration of the system "individual patient – non-invasive ICP meter".

The results of our clinical study (USAMRAA Award No: DAMD17-00-2-0065 (years 2001-2002), Clinical Research Protocol No. 99124006) support our hypotheses that the balance between ICP and extracranial pressure Pe applied to the eye can be achieved and identified applying multi-depth TCD technology with clinically non-significant systematic errors of absolute ICP measurement.

1.4. STATISTICAL TESTING OF THE HYPOTHESIS ON ZERO VALUE OF DIFFERENCES BETWEEN INVASIVE AND NON-INVASIVE ICP MEASUREMENTS

1.4.1. Testing the hypothesis

Testing the hypothesis on zero value of differences between the invasive and non-invasive ICP measurements (Table 2) is based on calculated value of the Student's *t* -test statistics:

$$T = \frac{m_D - 0}{\frac{s}{\sqrt{n}}},\tag{5}$$

which is distributed as Student's t with n-1 degrees of freedom.

Parameters m_D (mean) and S (standard deviation) are calculated using formulas:

$$m_D = \frac{1}{n} \sum_{i=1}^{n} D_i \,, \tag{6}$$

$$s = \sqrt{\frac{1}{n-1} \sum_{i=1}^{n} \left(D_i - m_D \right)^2} , \tag{7}$$

where D_i are measured values of differences.

The calculated value T is compared with the critical value t, obtained from the table of t -distribution values for the n-1 degrees of freedom and significance level of the test (size of the

critical region) α . If $|T| < t_{n-1, 1-\alpha/2}$, the hypothesis on the equality of the population means is accepted, otherwise the hypothesis is rejected.

By processing the data presented in Table 2 we obtain: n = 57, $m_D = 0.9386$ mmHg, s = 6.1775 mmHg and T = 1.1471.

The critical value of t-statistics for $\alpha = 5\%$ and n = 57 is $t_{n-1, 1-\alpha/2} \approx 2.00$.

$$|T| = 1.1471 < t_{n-1, 1-\alpha/2} = 2.00$$
 (8)

Therefore, the hypothesis on zero value of differences between invasive and non-invasive absolute ICP measurements under comparison is accepted.

1.4.2. Conclusion of clinical study

It is proved clinically for the first time that the non-invasive absolute ICP meter "Vittamed" is the only non-invasive ICP meter which does not need individual calibration of the system "patient – non-invasive ICP meter". The hypothesis on zero value of differences between invasive and non-invasive measurements has been proved by *t*-test statistics |T|=1.1471<2.0 (57 invasive / non-invasive measurements, ICP range from 4 mmHg to 33 mmHg, 10 patients, $\mu=0.939$ mmHg).

1.5. TECHNOLOGICAL REQUIREMENTS FOR NON-INVASIVE ABSOLUTE ICP METER PROTOTYPE DEVELOPMENT

The requirements for the development and design of the new more advanced deliverable prototype device for non-invasive absolute ICP measurement through the human eye are as follows:

- 1. To create an advanced software solution for on-line indication of spatial positioning and adjustment mode of ultrasonic transducer in order to obtain Doppler signals with the best signal to noise ratio from the two segments of the eye artery intracranial segment and extracranial segment simultaneously.
- 2. To create an advanced software solution for identification and interactive or automatic elimination of Doppler signal artifacts on-line and simultaneously in intracranial and extracranial segment of the eye artery.
- 3. To create an advanced software solution for Doppler frequency shift signal optimized filtering on-line. The non-standard pulsatility indexes should be calculated in real time and compared in the intracranial and extracranial segments of the eye artery after the optimized filtering procedures.
- 4. To create an advanced software solution for the automatic adjustment of the optimized filter by the patient's heart rate changes during TCD measurements.
- 5. To create advanced hardware and software solutions in order to identify the informative TCD signals superposed with disturbing echoes from various not moving anatomical reflectors and to select only the informative TCD signal in order to insure the proper accuracy of the ultrasonic signal processing in its receiver.
- 6. To improve the hardware solutions for the received ultrasound signal processing for better signal-to-noise ratio (at least two times better), better resolution (at least 3 4 times) for low

diastolic blood flow velocity values (less than 10 cm/s).

- 7. To create software solutions for the on-line indication of the point of balance between the intracranial pressure and pressure applied to the eye in order to indicate the non-invasively measured absolute ICP value at the point of balance.
- 8. To create the data transfer protocol and software solutions for the connection of the "black box"-type special two-depth TCD hardware to the notebook PC.

2.0. NON-INVASIVE ICP / VOLUME REAL-TIME MONITORING ASSESSMENT IN ICU

2.1. Background

A wide variation in autoregulatory status in patients with severe head injury makes the treatment based on targeting ICP or CPP far from optimal. According to this reasoning, when patients have a predominantly diffuse brain injury and exhibit the phenomenon of impaired cerebrovascular autoregulation (CA) the Lund (Sweden) approach may be an important option of patient treatment. The Lund approach is totally opposite to the targeting CPP approach. The Lund approach is based on the use of permissive low CPP if brain oxygen supply is sufficient. The application of different treatment strategies and fine-tuning the management of increased ICP can only be rationally applied if therapeutic decisions are based on the accurate knowledge of the autoregulatory status of the patient brain blood flow. In order to decide which approach of traumatic brain injury treatment for one or other autoregulatory state of one or another patient is suitable, it is necessary to use continuous cerebrovascular autoregulation state monitoring [15-29].

"Vittamed" time-of-flight non-invasive ICP / volume real-time slow wave monitoring technology (see our Annual Report Sept 2001, pp. 33-45) was clinically assessed at the first time during this clinical research study. The same technology was modified and used for simultaneous invasive and non-invasive cerebrovascular autoregulation continuous monitoring study in ICU.

2.2. Clinical study of non-invasive continuous slow intracranial blood volume waves monitoring and cerebrovascular autoregulation state monitoring

2.2.1. Clinical research objectives

(Clinical Research Protocol No.99124006, AIBS No.990135, HSSRB log No.A-9676):

To conduct a clinical trial on intensive care unit coma patients with head injuries and implanted existing standard invasive intracranial pressure (ICP) transducers connected to standard ICP monitors simultaneously with a new noninvasive ICP/volume monitor above the critical level ICP = 20...25 mmHg and below this level. To investigate the ability to apply a new noninvasive ICP/volume monitor for continuous monitoring of a head injured patient's cerebral blood flow autoregulation state.

2.2.2. Expected study population

(Clinical Research Protocol No.99124006, AIBS No.990135, HSSRB log No.A-9676):

Male and female subjects >18 years of age with traumatic brain injury.

We intended to study 10 patients with traumatic brain injury. Inclusion criteria: age >=18 years, brain injured patients monitored in an intensive care unit who have invasive arterial and intracranial pressure monitoring. Indications for intracranial pressure monitoring are appropriate in patients with severe head injury with abnormal admission CT scan. Severe head injury is defined as a Glasgow Coma Scale Score of 3-8 after cardiopulmonary resuscitation. An abnormal CT scan of the head is one that reveals hematomas, contusions, edema, or compressed basal cisterns. ICP monitoring is appropriate in patients with severe head injury with a normal CT scan if two or more of the following features are noted at admission: age over 40 years, unilateral or bilateral motor posturing, systolic blood pressure less than 90 mmHg. ICP monitoring is not routinely indicated in patients with mild or moderate head injury (Guidelines for the Management of Severe Head Injury. Brain Trauma Foundation, USA, 1995). Following

the Guidelines for the Management of Severe Head Injury, only comatose patients of ICU with implanted invasive ICP monitoring transducers will be involved in the study.

Post Sub-arachnoid haemorrhage patients monitored in an intensive care unit who have invasive arterial and intracranial pressure monitoring. Exclusion criteria: patients with wounds, scars or a craniotomy overlying the optimal window for transintracranial ultrasonic measurement.

2.2.3. Clinical data of non-invasive continuous slow intracranial blood volume waves monitoring and cerebrovascular autoregulation state monitoring

Clinical data have been obtained following Clinical Research Protocol No.99124006, AIBS No.990135, HSSRB log No.A-9676. Invasive ICP monitors Camino V420 and Codman ICP Express have been used simultaneously with the non-invasive "Vittamed" monitor in the ICU on coma patients. Study population is shown in Table 3.

Table 3. ICU patient population

Total	13
Gender: male/female	10 (76.9%) / 3(23.1%)
Age: Mean / Range	30.5/(18-64) years
Pathology: Closed severe traumatic brain injury	100 %
Mean ABP range, mmHg	35 – 140
Mean ICP range, mmHg	3 – 80
Cerebrovascular autoregulation simultaneous invasive and non-invasive monitoring	53 one hour sessions
Slow intracranial B waves simultaneous invasive and non-invasive monitoring	87 one hour sessions

Experimental data are shown in Appendix B and Appendix C.

2.2.4. Statistical evaluation of the clinical data

The two type data sets have been used for statistical evaluation. The first type data sets contain all measurement points of sampling period (Table 4). The second type data sets contain randomly selected data points (Table 5).

Table 4. Experimental data processing results

	Tuble 4. Daperimental data processing results							
Patient	Code of paired data set	Number of measurement points	Calculat Mean of differences	ion of test Standard deviation	statistics Value of t-criterion	Correlation coefficient		
1	2	3	4	5	6	7		
AB	ab2&ab3	703	-0.0047	0.4015	-0.3078	0.9194		
	ab4&5&6	703	-0.0046	0.5809	-0.2087	0.8313		
	ab6_part2&ab8	703	-0.0039	0.6629	-0.1542	0.7803		
AG	ag4_19part2	703	0.0045	0.9186	0.1304	0.5780		
	ag4_19part3	503	-0.0040	0.8418	-0.1075	0.6457		

AS	as1&as4_1	703	0.0030	0.8509	0.0937	0.6380
]	as2&as9	703	0.0099	0.8294	-0.3175	0.6560
	as3	703	-0.0026	0.6363	-0.1097	0.7976
	as4 2	700	0.0024	0.8065	0.0775	0.6748
ļ	as7 1	703	-0.0046	0.9805	-0.1248	0.5193
ŀ	as7 2	703	0.0022	1.0443	0.0557	0.4548
	as8 1	703	0.0033	0.6960	0.1246	0.7578
	as8 2	700	-0.0056	0.7358	-0.2022	0.7378
	as0_2 as10	700 701	0.0055	0.7338	l	
	•			I .	0.1565	0.5701
	as12	703	-0.0022	1.0564	-0.0541	0.4421
DJ	dj8	703	-0.0025	0.5090	-0.1285	0.8704
	dj13_15	703	0.0021	0.5320	0.1062	0.8585
	dj23_24	703	-0.0063	0.6321	-0.2641	0.8002
	dj28_32&dj44part1	703	-0.0036	0.3647	-0.2640	0.9335
	dj44part2&dj47_52	698	0.0017	0.6359	0.0709	0.7978
	dj57&dj59	703	0.0011	0.3806	0.0788	0.9276
	dj76-80	703	0.0178	0.9698	0.4863	0.5298
KV	kvl	703	-0.0019	0.7247	-0.0687	0.7374
	kv2_6part1	703	0.0056	0.7290	0.2040	0.7343
	kv2 6part2	687	-0.0036	0.4977	-0.1894	0.8761
MM	mm3 13part1	703	-0.0025	0.7086	-0.0934	0.7489
IVIIVI	mm55&mm59 1	703	0.0088	0.7080	0.2858	0.6674
		703 703	-0.0015	0.8130		
	mm57_1				-0.0418	0.5706
ł	mm57_2	703	0.00047	0.8543	0.0146	0.6351
	mm57_3	703 703	-0.0020	0.7913	-0.0666	0.6869
	mm57_5	703	0.000226	0.8923	0.0067	0.6019
1	mm59_2	703	-0.0044	0.7632	-0.1519	0,7088
	mm60_1	703	0.0022	0.7264	0.0818	0.7361
	mm60_2	701	-0.0016	0.7339	-0.0591	0,7307
	mm3_13part2&mm15_22	623	-0.0079	0.6977	-0.2816	0,7566
RM	rm_1v	703	0.0025	0.5109	0.1306	0.8695
	rm_2v	703	-0.0094	0.4497	-0.5542	0.8989
	rm_3v	703	-0.0069	0.3637	-0.5025	0.9339
	rm_4v	504	-0.0064	0.2785	0.5190	0.9612
	rm_g4g5g6	703	-0.0124	0.4743	-0.6925	0.8875
	rm-v100	703	-0.0010	0.2058	-0.1313	0.9788
) 	rm-101&v105&v106	703	-0.0100	0.4377	-0.6060	0.9042
	rm-v107&v119&v14	689	0.000186	0.4533	0.0108	0.8972
SL	sl2-3	703	0.0015	0.5032	0.0776	0.8734
JL.	s17	693	-0.0029	0.5068	0.1482	0.8716
	sl21 26part1	703	0.0018	0.2566	-0.1853	0.9671
	sl21_26part2	591	-0.0140	0.2508	-0.6198	0.8483
	sl28-33part1	703	-0.0027	0.5308	-0.1319	0.8503
1	sl28-33part2	697	0.0027	0.8394	0.1341	0.6477
	sl41&48	703	-0.0029	0.8394		
TID					-0.1044	0.7322
VD	vd11_26part1	703	0.0013	0.4169	0.0802	0.9131
	vd11_26part2	703	0.0032	0.4472	0.1894	0.9000
	vd11_26part3	703 504	-0.0016	0.3193	-0.1339	0.9490
	vd27_44part1	504	0.0024	0.3841	0.1685	0.9262
	vd27_44part2	703	0.0017	0.5306	0.0835	0.8592
	vd27_44part3	469	-0.0060	0.4384	-0.2974	0.9039
VG	vg4	703	-0.00028	0.8469	-0.0089	0.6413
	vg7&vg10part1	703	0.0062	0.4796	0.3408	0.8850
	vg10part2&vg2	703	-0.00015	0.4871	-0.0081	0.8814
	vg12	703	-0.000093	0.3784	-0.0065	0.9284
	vg15&18	703	-0.0203	0.8824	-0.6114	0.6107
	vg21part1	703	0.0076	0.9253	0.2173	0.5719
	vg21part2	703	0.0060	0.9580	0.1651	0.5411
	<u></u>					

VYB	vyb1_3	703	0.0013	0.6129	0.0542	0.8122
	vyb6	684	0.0021	0.2924	0.1834	0.9573
	vyb7	682	-0.0014	0.3049	-0.1235	0.9535
	vyb8	702	0.000935	0.2583	0.0959	0.9666
	vyb9_13	696	0.0066	0.5187	0.3334	0.8655
	vyb14&16	703	0.0073	0.6780	0.2837	0.7701
	vyb17_21	703	0.0015	0.2752	0.1461	0.9621
VM	vk1_3	703	-0.0056	0.6114	-0.2447	0.8131
	vm4&vm21_23	637	-0.000445	0.8477	-0.0132	0.6407
ĺ	vm5_10	703	0.0051	0.8433	0.1613	0.6445
	vm11	703	-0.0011	0.9820	-0.0293	0.5178
	vm12	692	0.0026	0.8511	0.0797	0.6378
	vm14_17part1	703	0.0043	0.5582	0.22204	0.8442
	vm14_17part2	703	0.0053	0.5340	0.2645	0.8574
	vm14_17part3	703	0.0051	0.5608	0.2390	0.8428
	vm14_17part4	703	0.0040	0.5773	0.1826	0.8334
	vm14_17part5	703	0.0014	0.6510	0.0574	0.7881
	vm20	703	-0.0038	0.5545	-0.1822	0.8462
JR	jr1-4_part1	703	0.0012	0.4783	0.0683	0.8856
	jr1-4_part2	703	-0.0019	0.4242	-0.1214	0.9100
	jr1-4_part3	635	0.0135	0.7042	0.4843	0.7521
	jr5-6	639	0.0027	0.5705	0.1175	0.8373
	jr7part1	703	0.0074	0.8344	0.2358	0.6519
	jr8	703	0.0053	0.8283	0.1708	0.6569

Table 5. Experimental data processing results

Designs Code of mained Number of Code at a table to									
Patient	Code of paired	Number of	Calculation of test statistics						
	data set	measurement	Mean of	Standard	Value of		Correlation		
		points	differences	deviation	t-cri	terion	coefficient		
1	2	3	4	5		6	7		
AB	ab2&ab3	70	-0.0965	0.3845		-2.0998	0.9314		
	ab4&5&6	70	-0.0280	0.6204	ľ	-0.3779	0.7899		
	ab6_part2&ab8	70	-0.0809	0.6553		-1.0325	0.7739		
AG	ag4 19part2	70	-0.0539	0.8261		-0.5458	0.6465		
	ag4_19part3	50	-0.0683	0.9008		-0.5365	0.5800		
AS	as1&as4_1	70	0.1181	0.7123		1.3868	0.7529		
	as2&as9	70	0.1399	0.9942		1.1771	0.5417		
	as3	70	0.0525	0.6376	1	0.6891	0.8043		
	as4_2	70	-0.0062	0.8502		-0.0608	0.6666		
	as7_1	70	-0.0391	0.9103	l	-0.3598	0.5484		
	as7_2	70	-0.1699	1.0513	ĺ	-1.3524	0.4511		
	as8_1	70	0.1301	0.6589	l	1.6517	0.7303		
	as8_2	70	-0.0354	0.9701		-1.1236	0.7549		
	as10	70	-0.1303	0.9273		0.1565	0.5064		
	as12	70	0.0030	0.9805		0.0254	0.4785		
DJ	dj8	70	-0.1231	0.5185		-1.9860	0.8895		
	dj13_15	70	0.0606	0.4898		1.0354	0.8463		
	dj23_24	70	-0.0371	0.5478		-0.5662	0.8536		
	dj28_32&dj44part1	70	0.0467	0.3387		1.1543	0.9500		
	dj44part2&dj47_52	69	-0.0132	0.4046	ł	-0.2700	0.8663		
	dj57&dj59	70	0.0018	0.3510		0.0418	0.9490		
	dj76-80	70	0.0467	1.0306		0.3791	0.5585		
KV	kv1	70	0.0639	0.7473		0.7149	0.7864		
_ ,	kv2_6part1	70	-0.0660	0.6520	- 1	-0.8465	0.7928		
	kv2_6part2	68	-0.0835	0.5073		-1.3573	0.8762		

MM	mm3 13part1	70	-0.0829	0.6270	-1.1060	0.8078
1,1,1,1	mm55&mm59 1	70	0.1160	0.9158	1.0595	0.6517
	mm57 1	70	-0.0416	0.9857	-0.3532	0.5377
1						
	mm57_2	70	0.0543	0.7987	0.5684	0.6828
	mm57_3	70	-0.0335	0.7485	-0.3748	0.7070
ļ	mm57 5	70	-0.0037	0.9102	-0.0338	0.6035
	mm59 ²	70	0.0485	0.6945	0.5841	0.7254
ł	mm60 1	70	0.0750	0.6301	0.9957	0.8225
		E		1		
	mm60_2	70	-0.0789	0.7419	-0.8898	0.7698
	mm3_13(2)&mm15_22	62	-0.1245	0.8585	-1.1422	0.6554
RM	rm 1v	70	-0.0584	0.4439	-1.1012	0.8903
1 1 1 1	rm 2v	70	-0.0648	0.5438	-0.9973	0.8615
	rm 3v	70	0.0402	0.3555	0.9453	0.9411
	· —				1	l .
	rm_4v	50	0.0109	0.2884	0.2663	0.9615
1	rm_g4g5g6	70	-0.0854	0.5054	-1.4146	0.8615
	rm-v100	70	-0.0058	0.2345	-0.2082	0.9654
	rm-v101&v105&v106	70	-0.0952	0.3886	-2.0494	0.9226
	rm-v107&v119&v14	68	-0.1056	0.4542	-1.9176	0.8723
CT		70		0.4264		
SL	sl2-3		0.0387		0.7594	0.9008
	sl7	69	0.0018	0.5049	0.0303	0.8800
	sl21_26part1	70	0.0396	0.2277	1,4533	0.9677
1	sl21 26part2	59	0.0593	0.5140	0.8865	0.6561
	sl28-33part1	70	0.0261	0.5626	0.3877	0.8692
i	sl28-33part2	69	0.0390	0.8199	0.3954	0.6882
	sl41&48	70	0.0846	0.6751	1,0481	0.8050
VD	vd11_26part1	70	-0.0188	0.3708	-0.4250	0.9340
'-	vd11 26part2	70	0.0557	0.5140	0,9065	0.8941
i	vd11 26part3	70	0.0446	0.3468	1.0756	0.9375
	vd27_44part1	70	0.0390	0.3958	0.8237	0.9312
				I	1	
	vd27_44part2	70	-0.0399	0.5174	-0.6460	0.8350
	vd27_44part3	46	-0.0235	0.3518	-0.4532	0.9041
VG	vg4	70	0.2077	0.7909	2,1971	0.7404
' "	vg7&vg10part1	70	0.0171	0.4492	0.3177	0.9061
	vg10part2&vg2	70	-0.0930	0.4575	-1.7010	0.8909
1	Vg10part2ccvg2		-0.0750		II .	0.0707
	1 12	1 70	0.0257	0.4217	I 0 700 4	0.0314
	vg12	70	-0.0357	0.4217	-0.7084	0.9214
	vg15&18	70	0.0662	0.8727	0.6349	0.7011
	vg15&18 vg21part1	70 70	0.0662 -0.0098	0.8727 1.0306		
	vg15&18	70	0.0662	0.8727	0,6349 -0.0792	0.7011 0.3985
VVR	vg15&18 vg21part1 vg21part2	70 70 70	0.0662 -0.0098 0.0831	0.8727 1.0306 0.9544	0.6349 -0.0792 0.7282	0,7011 0,3985 0,5861
VYB	vg15&18 vg21part1 vg21part2 vyb1_3	70 70 70 70	0.0662 -0.0098 0.0831 -0.0226	0.8727 1.0306 0.9544 0.6538	0.6349 -0.0792 0.7282 -0.2898	0.7011 0.3985 0.5861 0.8318
VYB	vg15&18 vg21part1 vg21part2 vyb1_3 vyb6	70 70 70 70 68	0.0662 -0.0098 0.0831 -0.0226 0.0844	0.8727 1.0306 0.9544 0.6538 0.2714	0.6349 -0.0792 0.7282 -0.2898 2.5638	0,7011 0,3985 0,5861 0,8318 0,9641
VYB	vg15&18 vg21part1 vg21part2 vyb1_3 vyb6 vyb7	70 70 70 70 68 68	0.0662 -0.0098 0.0831 -0.0226 0.0844 -0.0420	0.8727 1.0306 0.9544 0.6538 0.2714 0.2928	0.6349 -0.0792 0.7282 -0.2898 2.5638 -1.1830	0,7011 0,3985 0,5861 0,8318 0,9641 0,9608
VYB	vg15&18 vg21part1 vg21part2 vyb1_3 vyb6 vyb7 vyb8	70 70 70 70 68 68 70	0.0662 -0.0098 0.0831 -0.0226 0.0844 -0.0420 -0.0224	0.8727 1.0306 0.9544 0.6538 0.2714 0.2928 0.2590	0,6349 -0,0792 0,7282 -0,2898 2,5638 -1,1830 -0,7241	0,7011 0,3985 0,5861 0.8318 0,9641 0,9608 0,9688
VYB	vg15&18 vg21part1 vg21part2 vyb1_3 vyb6 vyb7	70 70 70 70 68 68 68 70 69	0.0662 -0.0098 0.0831 -0.0226 0.0844 -0.0420	0.8727 1.0306 0.9544 0.6538 0.2714 0.2928	0.6349 -0.0792 0.7282 -0.2898 2.5638 -1.1830	0,7011 0,3985 0,5861 0,8318 0,9641 0,9608
VYB	vg15&18 vg21part1 vg21part2 vyb1_3 vyb6 vyb7 vyb8 vyb9_13	70 70 70 70 68 68 70	0.0662 -0.0098 0.0831 -0.0226 0.0844 -0.0420 -0.0224	0.8727 1.0306 0.9544 0.6538 0.2714 0.2928 0.2590 0.4865	0.6349 -0.0792 0.7282 -0.2898 2.5638 -1.1830 -0.7241 -0.6599	0.7011 0.3985 0.5861 0.8318 0.9641 0.9608 0.9688 0.8734
VYB	vg15&18 vg21part1 vg21part2 vyb1_3 vyb6 vyb7 vyb8 vyb9_13 vyb14&16	70 70 70 70 68 68 70 69 70	0.0662 -0.0098 0.0831 -0.0226 0.0844 -0.0420 -0.0224 -0.0386 -0.0364	0.8727 1.0306 0.9544 0.6538 0.2714 0.2928 0.2590 0.4865 0.6126	0.6349 -0.0792 0.7282 -0.2898 2.5638 -1.1830 -0.7241 -0.6599 -0.4974	0.7011 0.3985 0.5861 0.8318 0.9641 0.9608 0.9688 0.8734 0.7915
	vg15&18 vg21part1 vg21part2 vyb1_3 vyb6 vyb7 vyb8 vyb9_13 vyb14&16 vyb17_21	70 70 70 70 68 68 70 69 70	0.0662 -0.0098 0.0831 -0.0226 0.0844 -0.0420 -0.0224 -0.0386 -0.0364 0.0081	0.8727 1.0306 0.9544 0.6538 0.2714 0.2928 0.2590 0.4865 0.6126 0.2757	0.6349 -0.0792 0.7282 -0.2898 2.5638 -1.1830 -0.7241 -0.6599 -0.4974 0.2445	0.7011 0.3985 0.5861 0.8318 0.9641 0.9608 0.9688 0.8734 0.7915 0.9598
VYB	vg15&18 vg21part1 vg21part2 vyb1_3 vyb6 vyb7 vyb8 vyb9_13 vyb14&16 vyb17_21 vk1_3	70 70 70 70 68 68 70 69 70 70	0.0662 -0.0098 0.0831 -0.0226 0.0844 -0.0420 -0.0224 -0.0386 -0.0364 0.0081	0.8727 1.0306 0.9544 0.6538 0.2714 0.2928 0.2590 0.4865 0.6126 0.2757	0,6349 -0,0792 0,7282 -0,2898 2,5638 -1,1830 -0,7241 -0,6599 -0,4974 0,2445 -1,4220	0.7011 0.3985 0.5861 0.8318 0.9641 0.9608 0.9688 0.8734 0.7915 0.9598
	vg15&18 vg21part1 vg21part2 vyb1_3 vyb6 vyb7 vyb8 vyb9_13 vyb14&16 vyb17_21 vk1_3 vm4&vm21_23	70 70 70 70 68 68 68 70 69 70 70 70	0.0662 -0.0098 0.0831 -0.0226 0.0844 -0.0420 -0.0224 -0.0386 -0.0364 0.0081 -0.0911 -0.0921	0.8727 1.0306 0.9544 0.6538 0.2714 0.2928 0.2590 0.4865 0.6126 0.2757 0.5358 0.7063	0.6349 -0.0792 0.7282 -0.2898 2.5638 -1.1830 -0.7241 -0.6599 -0.4974 0.2445	0.7011 0.3985 0.5861 0.8318 0.9641 0.9608 0.9688 0.8734 0.7915 0.9598 0.8330 0.7612
	vg15&18 vg21part1 vg21part2 vyb1_3 vyb6 vyb7 vyb8 vyb9_13 vyb14&16 vyb17_21 vk1_3 vm4&vm21_23 vm5_10	70 70 70 70 68 68 68 70 69 70 70 70 63 70	0.0662 -0.0098 0.0831 -0.0226 0.0844 -0.0420 -0.0224 -0.0386 -0.0364 0.0081 -0.0911 -0.0921 0.0375	0.8727 1.0306 0.9544 0.6538 0.2714 0.2928 0.2590 0.4865 0.6126 0.2757 0.5358 0.7063 0.8380	0,6349 -0,0792 0,7282 -0,2898 2,5638 -1,1830 -0,7241 -0,6599 -0,4974 0,2445 -1,4220 -1,0349	0.7011 0.3985 0.5861 0.8318 0.9641 0.9608 0.9688 0.8734 0.7915 0.9598
	vg15&18 vg21part1 vg21part2 vyb1_3 vyb6 vyb7 vyb8 vyb9_13 vyb14&16 vyb17_21 vk1_3 vm4&vm21_23	70 70 70 70 68 68 68 70 69 70 70 70	0.0662 -0.0098 0.0831 -0.0226 0.0844 -0.0420 -0.0224 -0.0386 -0.0364 0.0081 -0.0911 -0.0921	0.8727 1.0306 0.9544 0.6538 0.2714 0.2928 0.2590 0.4865 0.6126 0.2757 0.5358 0.7063	0,6349 -0,0792 0,7282 -0,2898 2,5638 -1,1830 -0,7241 -0,6599 -0,4974 0,2445 -1,4220 -1,0349 0,3739	0.7011 0.3985 0.5861 0.8318 0.9641 0.9608 0.9688 0.8734 0.7915 0.9598 0.8330 0.7612
	vg15&18 vg21part1 vg21part2 vyb1_3 vyb6 vyb7 vyb8 vyb9_13 vyb14&16 vyb17_21 vk1_3 vm4&vm21_23 vm5_10 vm11	70 70 70 70 68 68 68 70 69 70 70 70 63 70	0.0662 -0.0098 0.0831 -0.0226 0.0844 -0.0420 -0.0224 -0.0386 -0.0364 0.0081 -0.0911 -0.0921 0.0375 -0.0217	0.8727 1.0306 0.9544 0.6538 0.2714 0.2928 0.2590 0.4865 0.6126 0.2757 0.5358 0.7063 0.8380 0.9035	0,6349 -0,0792 0,7282 -0,2898 2,5638 -1,1830 -0,7241 -0,6599 -0,4974 0,2445 -1,4220 -1,0349 0,3739 -0,2006	0,7011 0,3985 0,5861 0,8318 0,9641 0,9608 0,9688 0,8734 0,7915 0,9598 0,8330 0,7612 0,6113 0,4771
	vg15&18 vg21part1 vg21part2 vyb1_3 vyb6 vyb7 vyb8 vyb9_13 vyb14&16 vyb17_21 vk1_3 vm4&vm21_23 vm5_10 vm11 vm12	70 70 70 70 68 68 68 70 69 70 70 63 70 70 69	0.0662 -0.0098 0.0831 -0.0226 0.0844 -0.0420 -0.0224 -0.0386 -0.0364 0.0081 -0.0911 -0.0921 0.0375 -0.0217 0.0017	0.8727 1.0306 0.9544 0.6538 0.2714 0.2928 0.2590 0.4865 0.6126 0.2757 0.5358 0.7063 0.8380 0.9035 0.7195	0.6349 -0.0792 0.7282 -0.2898 2.5638 -1.1830 -0.7241 -0.6599 -0.4974 0.2445 -1.4220 -1.0349 0.3739 -0.2006 0.0194	0,7011 0,3985 0,5861 0,8318 0,9641 0,9608 0,9688 0,8734 0,7915 0,9598 0,8330 0,7612 0,6113 0,4771 0,7339
	vg15&18 vg21part1 vg21part2 vyb1_3 vyb6 vyb7 vyb8 vyb9_13 vyb14&16 vyb17_21 vk1_3 vm4&vm21_23 vm5_10 vm11 vm12 vm14_17part1	70 70 70 70 68 68 68 70 69 70 70 63 70 70 69 70	0.0662 -0.0098 0.0831 -0.0226 0.0844 -0.0420 -0.0224 -0.0386 -0.0364 0.0081 -0.0921 0.0375 -0.0217 0.0017 -0.0612	0.8727 1.0306 0.9544 0.6538 0.2714 0.2928 0.2590 0.4865 0.6126 0.2757 0.5358 0.7063 0.8380 0.9035 0.7195 0.5144	0.6349 -0.0792 0.7282 -0.2898 2.5638 -1.1830 -0.7241 -0.6599 -0.4974 0.2445 -1.4220 -1.0349 0.3739 -0.2006 0.0194 -0.9950	0,7011 0,3985 0,5861 0,8318 0,9641 0,9608 0,9688 0,8734 0,7915 0,9598 0,8330 0,7612 0,6113 0,4771 0,7339 0,8821
	vg15&18 vg21part1 vg21part2 vyb1_3 vyb6 vyb7 vyb8 vyb9_13 vyb14&16 vyb17_21 vk1_3 vm4&vm21_23 vm5_10 vm11 vm12 vm14_17part1 vm14_17part2	70 70 70 70 68 68 68 70 69 70 70 63 70 70 69 70	0.0662 -0.0098 0.0831 -0.0226 0.0844 -0.0420 -0.0224 -0.0386 -0.0364 0.0081 -0.0911 -0.0921 0.0375 -0.0217 0.0017 -0.0612 0.0239	0.8727 1.0306 0.9544 0.6538 0.2714 0.2928 0.2590 0.4865 0.6126 0.2757 0.5358 0.7063 0.8380 0.9035 0.7195 0.5144 0.5684	0.6349 -0.0792 0.7282 -0.2898 2.5638 -1.1830 -0.7241 -0.6599 -0.4974 0.2445 -1.4220 -1.0349 0.3739 -0.2006 0.0194	0,7011 0,3985 0,5861 0,8318 0,9641 0,9608 0,9688 0,8734 0,7915 0,9598 0,8330 0,7612 0,6113 0,4771 0,7339 0,8821 0,8511
	vg15&18 vg21part1 vg21part2 vyb1_3 vyb6 vyb7 vyb8 vyb9_13 vyb14&16 vyb17_21 vk1_3 vm4&vm21_23 vm5_10 vm11 vm12 vm14_17part1 vm14_17part2 vm14_17part3	70 70 70 70 68 68 68 70 69 70 70 63 70 70 69 70 70	0.0662 -0.0098 0.0831 -0.0226 0.0844 -0.0420 -0.0224 -0.0386 -0.0364 0.0081 -0.0911 -0.0921 0.0375 -0.0217 0.0017 -0.0612 0.0239 -0.0398	0.8727 1.0306 0.9544 0.6538 0.2714 0.2928 0.2590 0.4865 0.6126 0.2757 0.5358 0.7063 0.8380 0.9035 0.7195 0.5144 0.5684 0.5921	0.6349 -0.0792 0.7282 -0.2898 2.5638 -1.1830 -0.7241 -0.6599 -0.4974 0.2445 -1.4220 -1.0349 0.3739 -0.2006 0.0194 -0.9950	0.7011 0.3985 0.5861 0.8318 0.9641 0.9608 0.9688 0.8734 0.7915 0.9598 0.8330 0.7612 0.6113 0.4771 0.7339 0.8821 0.8511 0.8134
	vg15&18 vg21part1 vg21part2 vyb1_3 vyb6 vyb7 vyb8 vyb9_13 vyb14&16 vyb17_21 vk1_3 vm4&vm21_23 vm5_10 vm11 vm12 vm14_17part1 vm14_17part2	70 70 70 70 68 68 68 70 69 70 70 63 70 70 69 70	0.0662 -0.0098 0.0831 -0.0226 0.0844 -0.0420 -0.0224 -0.0386 -0.0364 0.0081 -0.0911 -0.0921 0.0375 -0.0217 0.0017 -0.0612 0.0239	0.8727 1.0306 0.9544 0.6538 0.2714 0.2928 0.2590 0.4865 0.6126 0.2757 0.5358 0.7063 0.8380 0.9035 0.7195 0.5144 0.5684	0.6349 -0.0792 0.7282 -0.2898 2.5638 -1.1830 -0.7241 -0.6599 -0.4974 0.2445 -1.4220 -1.0349 0.3739 -0.2006 0.0194 -0.9950 0.3525 -0.5626	0,7011 0,3985 0,5861 0,8318 0,9641 0,9608 0,9688 0,8734 0,7915 0,9598 0,8330 0,7612 0,6113 0,4771 0,7339 0,8821 0,8511
	vg15&18 vg21part1 vg21part2 vyb1_3 vyb6 vyb7 vyb8 vyb9_13 vyb14&16 vyb17_21 vk1_3 vm4&vm21_23 vm5_10 vm11 vm12 vm14_17part1 vm14_17part2 vm14_17part3 vm14_17part4	70 70 70 70 68 68 68 70 69 70 70 63 70 70 69 70 70 70	0.0662 -0.0098 0.0831 -0.0226 0.0844 -0.0420 -0.0224 -0.0386 -0.0364 0.0081 -0.0911 -0.0921 0.0375 -0.0217 0.0017 -0.0612 0.0239 -0.0398 -0.0877	0.8727 1.0306 0.9544 0.6538 0.2714 0.2928 0.2590 0.4865 0.6126 0.2757 0.5358 0.7063 0.8380 0.9035 0.7195 0.5144 0.5684 0.5921 0.5817	0,6349 -0,0792 0,7282 -0,2898 2,5638 -1,1830 -0,7241 -0,6599 -0,4974 0,2445 -1,4220 -1,0349 0,3739 -0,2006 0,0194 -0,9950 0,3525 -0,5626 -1,2612	0.7011 0.3985 0.5861 0.8318 0.9641 0.9608 0.9688 0.8734 0.7915 0.9598 0.8330 0.7612 0.6113 0.4771 0.7339 0.8821 0.8511 0.8134 0.8172
	vg15&18 vg21part1 vg21part2 vyb1_3 vyb6 vyb7 vyb8 vyb9_13 vyb14&16 vyb17_21 vk1_3 vm4&vm21_23 vm5_10 vm11 vm12 vm14_17part1 vm14_17part2 vm14_17part3 vm14_17part4 vm14_17part4	70 70 70 70 68 68 68 70 69 70 70 63 70 70 69 70 70 70 70	0.0662 -0.0098 0.0831 -0.0226 0.0844 -0.0420 -0.0224 -0.0386 -0.0364 0.0081 -0.0911 -0.0921 0.0375 -0.0217 0.0017 -0.0612 0.0239 -0.0398 -0.0877 -0.0178	0.8727 1.0306 0.9544 0.6538 0.2714 0.2928 0.2590 0.4865 0.6126 0.2757 0.5358 0.7063 0.8380 0.9035 0.7195 0.5144 0.5684 0.5921 0.5817 0.6853	0,6349 -0,0792 0,7282 -0,2898 2,5638 -1,1830 -0,7241 -0,6599 -0,4974 0,2445 -1,4220 -1,0349 0,3739 -0,2006 0,0194 -0,9950 0,3525 -0,5626 -1,2612 -0,2173	0.7011 0.3985 0.5861 0.8318 0.9641 0.9608 0.9688 0.8734 0.7915 0.9598 0.8330 0.7612 0.6113 0.4771 0.7339 0.8821 0.8511 0.8134 0.8172 0.7385
VM	vg15&18 vg21part1 vg21part2 vyb1_3 vyb6 vyb7 vyb8 vyb9_13 vyb14&16 vyb17_21 vk1_3 vm4&vm21_23 vm5_10 vm11 vm12 vm14_17part1 vm14_17part2 vm14_17part3 vm14_17part4 vm14_17part5 vm20	70 70 70 70 68 68 68 70 69 70 70 63 70 70 69 70 70 70 70	0.0662 -0.0098 0.0831 -0.0226 0.0844 -0.0420 -0.0224 -0.0386 -0.0364 0.0081 -0.0911 -0.0921 0.0375 -0.0217 0.0017 -0.0612 0.0239 -0.0398 -0.0877 -0.0178 -0.0223	0.8727 1.0306 0.9544 0.6538 0.2714 0.2928 0.2590 0.4865 0.6126 0.2757 0.5358 0.7063 0.8380 0.9035 0.7195 0.5144 0.5684 0.5921 0.5817 0.6853 0.5022	0,6349 -0,0792 0,7282 -0,2898 2,5638 -1,1830 -0,7241 -0,6599 -0,4974 0,2445 -1,4220 -1,0349 0,3739 -0,2006 0,0194 -0,9950 0,3525 -0,5626 -1,2612 -0,2173 -0,3711	0,7011 0,3985 0,5861 0,8318 0,9641 0,9608 0,9688 0,8734 0,7915 0,9598 0,8330 0,7612 0,6113 0,4771 0,7339 0,8821 0,8134 0,8172 0,7385 0,8554
	vg15&18 vg21part1 vg21part2 vyb1_3 vyb6 vyb7 vyb8 vyb9_13 vyb14&16 vyb17_21 vk1_3 vm4&vm21_23 vm5_10 vm11 vm12 vm14_17part1 vm14_17part2 vm14_17part3 vm14_17part4 vm14_17part5 vm20 jr1-4_part1	70 70 70 70 68 68 68 70 69 70 70 63 70 70 69 70 70 70 70 70 70 70 70 70 70 70 70	0.0662 -0.0098 0.0831 -0.0226 0.0844 -0.0420 -0.0224 -0.0386 -0.0364 0.0081 -0.0911 -0.0921 0.0375 -0.0217 0.0017 -0.0612 0.0239 -0.0398 -0.0378 -0.0178 -0.0178 -0.0178 -0.0178 -0.01027	0.8727 1.0306 0.9544 0.6538 0.2714 0.2928 0.2590 0.4865 0.6126 0.2757 0.5358 0.7063 0.8380 0.9035 0.7195 0.5144 0.5684 0.5921 0.5817 0.6853 0.5022	0,6349 -0,0792 0,7282 -0,2898 2,5638 -1,1830 -0,7241 -0,6599 -0,4974 0,2445 -1,4220 -1,0349 0,3739 -0,2006 0,0194 -0,9950 0,3525 -0,5626 -1,2612 -0,2173 -0,3711 -1,7979	0,7011 0,3985 0,5861 0,8318 0,9641 0,9608 0,9688 0,8734 0,7915 0,9598 0,8330 0,7612 0,6113 0,4771 0,7339 0,8821 0,8511 0,8134 0,8172 0,7385 0,8554
VM	vg15&18 vg21part1 vg21part2 vyb1_3 vyb6 vyb7 vyb8 vyb9_13 vyb14&16 vyb17_21 vk1_3 vm4&vm21_23 vm5_10 vm11 vm12 vm14_17part1 vm14_17part2 vm14_17part3 vm14_17part4 vm14_17part5 vm20	70 70 70 70 68 68 68 70 69 70 70 63 70 70 69 70 70 70 70	0.0662 -0.0098 0.0831 -0.0226 0.0844 -0.0420 -0.0224 -0.0386 -0.0364 0.0081 -0.0911 -0.0921 0.0375 -0.0217 0.0017 -0.0612 0.0239 -0.0398 -0.0877 -0.0178 -0.0223	0.8727 1.0306 0.9544 0.6538 0.2714 0.2928 0.2590 0.4865 0.6126 0.2757 0.5358 0.7063 0.8380 0.9035 0.7195 0.5144 0.5684 0.5921 0.5817 0.6853 0.5022	0,6349 -0,0792 0,7282 -0,2898 2,5638 -1,1830 -0,7241 -0,6599 -0,4974 0,2445 -1,4220 -1,0349 0,3739 -0,2006 0,0194 -0,9950 0,3525 -0,5626 -1,2612 -0,2173 -0,3711	0,7011 0,3985 0,5861 0,8318 0,9641 0,9608 0,9688 0,8734 0,7915 0,9598 0,8330 0,7612 0,6113 0,4771 0,7339 0,8821 0,8134 0,8172 0,7385 0,8554
VM	vg15&18 vg21part1 vg21part2 vyb1_3 vyb6 vyb7 vyb8 vyb9_13 vyb14&16 vyb17_21 vk1_3 vm4&vm21_23 vm5_10 vm11 vm12 vm14_17part1 vm14_17part2 vm14_17part2 vm14_17part3 vm14_17part4 vm14_17part5 vm20 jr1-4_part1 jr1-4_part2	70 70 70 70 68 68 68 70 69 70 70 63 70 70 69 70 70 70 70 70 70 70 70 70 70 70 70 70	0.0662 -0.0098 0.0831 -0.0226 0.0844 -0.0420 -0.0224 -0.0386 -0.0364 0.0081 -0.0911 -0.0921 0.0375 -0.0217 0.0017 -0.0612 0.0239 -0.0398 -0.0398 -0.0375 -0.0178 -0.0017 -0.0178 -0.00223	0.8727 1.0306 0.9544 0.6538 0.2714 0.2928 0.2590 0.4865 0.6126 0.2757 0.5358 0.7063 0.8380 0.9035 0.7195 0.5144 0.5684 0.5921 0.5817 0.6853 0.5022 0.4777 0.4206	0.6349 -0.0792 0.7282 -0.2898 2.5638 -1.1830 -0.7241 -0.6599 -0.4974 0.2445 -1.4220 -1.0349 0.3739 -0.2006 0.0194 -0.9950 0.3525 -0.5626 -1.2612 -0.2173 -0.3711 -1.7979 -0.0671	0,7011 0,3985 0,5861 0,8318 0,9641 0,9608 0,9688 0,8734 0,7915 0,9598 0,8330 0,7612 0,6113 0,4771 0,7339 0,8821 0,8511 0,8134 0,8172 0,7385 0,8554
VM	vg15&18 vg21part1 vg21part2 vyb1_3 vyb6 vyb7 vyb8 vyb9_13 vyb14&16 vyb17_21 vk1_3 vm4&vm21_23 vm5_10 vm11 vm12 vm14_17part1 vm14_17part2 vm14_17part3 vm14_17part4 vm14_17part5 vm20 jr1-4_part1 jr1-4_part2 jr1-4_part3	70 70 70 70 68 68 68 70 69 70 70 63 70 70 69 70 70 70 70 70 70 70 70 70 70 70 70 70	0.0662 -0.0098 0.0831 -0.0226 0.0844 -0.0420 -0.0224 -0.0386 -0.0364 0.0081 -0.0911 -0.0921 0.0375 -0.0217 0.0017 -0.0612 0.0239 -0.0398 -0.0877 -0.0178 -0.0223 -0.1027 -0.0034 0.0430	0.8727 1.0306 0.9544 0.6538 0.2714 0.2928 0.2590 0.4865 0.6126 0.2757 0.5358 0.7063 0.8380 0.9035 0.7195 0.5144 0.5684 0.5921 0.5817 0.6853 0.5022 0.4777 0.4206 0.6655	0.6349 -0.0792 0.7282 -0.2898 2.5638 -1.1830 -0.7241 -0.6599 -0.4974 0.2445 -1.4220 -1.0349 0.3739 -0.2006 0.0194 -0.9950 0.3525 -0.5626 -1.2612 -0.2173 -0.3711 -1.7979 -0.0671 0.5126	0.7011 0.3985 0.5861 0.8318 0.9641 0.9608 0.9688 0.8734 0.7915 0.9598 0.8330 0.7612 0.6113 0.4771 0.7339 0.8821 0.8511 0.8134 0.8172 0.7385 0.8767 0.9200 0.7949
VM	vg15&18 vg21part1 vg21part2 vyb1_3 vyb6 vyb7 vyb8 vyb9_13 vyb14&16 vyb17_21 vk1_3 vm4&vm21_23 vm5_10 vm11 vm12 vm14_17part1 vm14_17part2 vm14_17part2 vm14_17part3 vm14_17part5 vm20 jr1-4_part1 jr1-4_part3 jr5-6	70 70 70 70 68 68 68 70 69 70 70 63 70 70 70 70 70 70 70 70 70 70 70 70 70	0.0662 -0.0098 0.0831 -0.0226 0.0844 -0.0420 -0.0224 -0.0386 -0.0364 0.0081 -0.0911 -0.0921 0.0375 -0.0217 0.0017 -0.0612 0.0239 -0.0398 -0.0877 -0.0178 -0.0223 -0.1027 -0.0034 0.0430 -0.0545	0.8727 1.0306 0.9544 0.6538 0.2714 0.2928 0.2590 0.4865 0.6126 0.2757 0.5358 0.7063 0.8380 0.9035 0.7195 0.5144 0.5684 0.5921 0.5817 0.6853 0.5022 0.4777 0.4206 0.6655 0.5714	0.6349 -0.0792 0.7282 -0.2898 2.5638 -1.1830 -0.7241 -0.6599 -0.4974 0.2445 -1.4220 -1.0349 0.3739 -0.2006 0.0194 -0.9950 0.3525 -0.5626 -1.2612 -0.2173 -0.3711 -1.7979 -0.0671 0.5126 -0.7566	0.7011 0.3985 0.5861 0.8318 0.9641 0.9608 0.9688 0.8734 0.7915 0.9598 0.8330 0.7612 0.6113 0.4771 0.7339 0.8821 0.8511 0.8134 0.8172 0.7385 0.8554 0.8767 0.9200 0.7949 0.8232
VM	vg15&18 vg21part1 vg21part2 vyb1_3 vyb6 vyb7 vyb8 vyb9_13 vyb14&16 vyb17_21 vk1_3 vm4&vm21_23 vm5_10 vm11 vm12 vm14_17part1 vm14_17part2 vm14_17part3 vm14_17part4 vm14_17part5 vm20 jr1-4_part1 jr1-4_part2 jr1-4_part3	70 70 70 70 68 68 68 70 69 70 70 63 70 70 69 70 70 70 70 70 70 70 70 70 70 70 70 70	0.0662 -0.0098 0.0831 -0.0226 0.0844 -0.0420 -0.0224 -0.0386 -0.0364 0.0081 -0.0911 -0.0921 0.0375 -0.0217 0.0017 -0.0612 0.0239 -0.0398 -0.0877 -0.0178 -0.0223 -0.1027 -0.0034 0.0430	0.8727 1.0306 0.9544 0.6538 0.2714 0.2928 0.2590 0.4865 0.6126 0.2757 0.5358 0.7063 0.8380 0.9035 0.7195 0.5144 0.5684 0.5921 0.5817 0.6853 0.5022 0.4777 0.4206 0.6655	0.6349 -0.0792 0.7282 -0.2898 2.5638 -1.1830 -0.7241 -0.6599 -0.4974 0.2445 -1.4220 -1.0349 0.3739 -0.2006 0.0194 -0.9950 0.3525 -0.5626 -1.2612 -0.2173 -0.3711 -1.7979 -0.0671 0.5126	0.7011 0.3985 0.5861 0.8318 0.9641 0.9608 0.9688 0.8734 0.7915 0.9598 0.8330 0.7612 0.6113 0.4771 0.7339 0.8821 0.8511 0.8134 0.8172 0.7385 0.8767 0.9200 0.7949

The values of *t*-criterion corresponding to each data set have been calculated using normalized data. Normalization was performed by division the original measurement data by standard deviation. The calculated values of *t*-criterion, presented in Tables 4, 5, are checked on meeting the inequality:

$$|t| < T_{crit}, \tag{9}$$

where t is calculated value of t-criterion for paired or correlated samples [44], and T_{crit} is critical value of t-statistic [44]:

$$T_{crit} = 1.960 \text{ for } \alpha = 0.05, n > 120,$$
 (10)

$$T_{crit} = 1.997 \text{ for } \alpha = 0.05, n = 70,$$
 (11)

$$T_{crit} = 2.000 \text{ for } \alpha = 0.05, n = 60,$$
 (12)

$$T_{crit} = 2.010 \text{ for } \alpha = 0.05, n = 50,$$
 (13)

$$T_{crit} = 2.021$$
 for $\alpha = 0.05$, $n = 40$, (14)

 α is the significance level of the test (size of the critical region), n is the number of measurement points.

If the condition (9) is satisfied, the hypothesis on equality of the mean values of measurements under comparison is accepted, otherwise the hypothesis is rejected.

The investigated number of samples is N = 87 and the number of samples that meet the condition (9) in Table 5 is $N_{+} = 83$. The proportion of samples with positive decision is

$$\pi_{N+} = \frac{N_+}{N} = 0.954. \tag{15}$$

The calculated value π_{N+} is more than the proportion of interest $\pi = 0.95$:

$$\pi_{N+} = 0.954 > \pi = 0.95$$
 (16)

So, the hypothesis on the coincidence of measurement results is accepted.

2.2.5. Analysis of clinical data

In order to determine the metrological requirements for the deliverable prototype for non-invasive CA monitoring device, the clinical data of this research were analyzed. The results of analysis are shown in Fig. 11 - Fig. 19.

The main results of analysis are as follows:

- in order to obtain correlation coefficient between invasively and non-invasively recorded slow ICP and slow cerebral blood volume waves better than $r \ge 0.9$, it is necessary to perform the monitoring when the amplitude of ICP B waves is more than 3.0 mmHg (Fig. 11). The standard deviation of the correlation coefficient r is also minimal in this case (Fig. 12),
- the same conclusion about the acceptable amplitude of permanent or interminent ICP B waves follows from Fig. 14 concerning the standard deviation of the difference between invasively and non-invasively measured cerebrovascular autoregulation state indices,
- it follows from Fig. 16 that the acceptable ABP slow wave amplitude is more than 5.0 mmHg,
- it has been shown experimentally (Fig. 17, Fig. 18) that the difference between invasively and

non-invasively measured CA indices expressed by the standard deviation σ (Fig. 18) decreases significantly when the autoregulation state has a tendency to be impaired ($r \rightarrow +1.0$) or to be intact ($r \rightarrow -1.0$). In both clinically important cases the random error values expressed by σ are not significant in the clinical practice. The systematic error Δ (Fig. 17, Fig. 19) is also not important in the clinical practice.




Fig. 11. Mean value of the correlation coefficient between invasive ICP B waves and non-invasively measured intracranial blood volume B waves depending on the amplitude of the ICP B waves (13 patients, 87 hours of simultaneous invasive ICP and non-invasive US monitoring, 2631 experimental data points)




Fig. 12. Standard deviation of the correlation coefficient between invasive ICP B waves and non-invasive ultrasound speed B waves depending on the amplitude of the ICP B waves (13 patients, 87 hours of simultaneous invasive ICP and non-invasive US monitoring)




Fig. 13. Mean value of the difference between invasive and non-invasive CA estimating indices depending on the amplitude of ICP B waves (10 patients, 53 hours of simultaneous invasive and non-invasive CA monitoring)




Fig. 14. Standard deviation of the difference between invasive and non-invasive CA estimating indices depending on the amplitude of ICP B waves (10 patients, 53 hours of simultaneous invasive and non-invasive CA monitoring)




Fig. 15. Mean value of the difference between invasive and non-invasive CA estimating indices depending on the amplitude of ABP B waves (10 patients, 53 hours of simultaneous invasive and non-invasive CA monitoring)




Fig.16. Standard deviation of the difference between invasive and non-invasive CA estimating indices depending on the amplitude of ABP B waves (10 patients, 53 hours of simultaneous invasive and non-invasive CA monitoring)




Fig. 17. Estimation of the similarity between invasive and non-invasive CA estimating indices r(ABP, ICP) and r(ABP, US): Bland Altman plot comparing invasive and non-invasive data (10 patients, 53 hours of simultaneous invasive and non-invasive CA monitoring, 1570 experimental data points of CA estimation)




Fig. 18. Standard deviation of the difference between invasive and non-invasive CA estimation indices calculated from Bland Altman plot of r(ABP,ICP) and r(ABP,US) (10 patients, 53 hours of simultaneous invasive and non-invasive CA monitoring)




Fig. 19. Estimation of the similarity between invasive and non-invasive CA estimating indices r(ABP, ICP) and r(ABP, US): a) - distribution of differences between the invasive and non-invasive data, b) - Bland Altman plot comparing invasive and non-invasive data (10 patients, 53 hours of simultaneous invasive and non-invasive CA monitoring, 1570 experimental data points of CA estimation)

2.2.6. Conclusion of clinical study

It is proved clinically for the first time that the non-invasive intracranial blood volume slow wave monitor "Vittamed" can be used under ICU conditions for the reliable short- or long-term continuous non-invasive cerebrovascular autoregulation monitoring.

For statistical analysis the same methodology was used as described in paragraphs 1.3.3 - 1.3.5.

Statistically significant estimation (13 patients) shows that the hypothesis of the coincidence of invasively and non-invasively measured ICP and IBV slow wave data is accepted (π >0.95). Statistically estimated (Bland Altman) difference between invasively and non-invasively recorded intracranial slow waves (SD=0.089, p=4.5x10⁻⁷) and the difference between invasively and non-invasively recorded cerebral autoregulation indexes (SD=0.05, p=1.1x10⁻⁶) is small enough and such differences are not clinically important.

In this clinical study the statistically significant evidences were obtained at the first time that ultrasonographic time-of-flight technology "Vittamed" could be applied for non-invasive continuous cerebrovascular autoregulation monitoring.

2.3. TECHNOLOGICAL REQUIREMENTS FOR NON-INVASIVE CEREBROVASCULAR AUTOREGULATION MONITOR PROTOTYPE DEVELOPMENT

The requirements for the development and design of the new more advanced deliverable prototype device for cerebrovascular autoregulation monitoring are as follows:

- to include into a cerebrovascular autoregulation monitor a non-invasive arterial blood pressure (ABP) monitoring (replacement of invasive ABP line) transducer for slow ABP waves monitoring with the possibility to monitor slow ABP waves with amplitudes from 1 mmHg to 10 mmHg,

- to improve the hardware and software solutions in order to increase the accuracy of an automatic compensation of the influence of blood flow in the extracranial tissues inside the acoustic path . It is necessary to identify automatically the quality of the received ultrasonic echo signals from the internal surfaces of skull bones and dura mater.
- to improve the software solutions for automatic ultrasonic signal quality identification on-line and to improve an automatic adjustment of the zero crossing points in the received signals in order to determine the artifacts during the cerebrovascular autoregulation state monitoring,
- to improve the software solutions for the estimation of the shape and amplitude of measured slow intracranial blood volume B waves and slow ABP waves with the necessary accuracy,
- to improve a mechanical frame for ultrasonic transducers fixation on the human head in order to increase comfort for the patient under monitoring,
- to create the data transfer protocol and software solutions for connection of ultrasonic transducers with "black box"-type interfacing hardware which will be connected to a notebook PC for data processing and non-invasive cerebrovascular autoregulation state indication on-line in numerical form.

3. KEY RESEARCH ACCOMPLISHMENTS (Performance period 1 October 2001 – 1 October 2002)

- 1.0. Approved statement of work: non-invasive ICP measurement through the human eye.
- 1.5. Perform clinical evaluation of the prototype and the clinical study.

Accomplishment: the prototype has been evaluated in ICU. Clinical study of invasive and non-invasive measurement of absolute ICP has been performed in ICU. 57 simultaneous invasive and non-invasive absolute ICP measurements have been performed on 10 ICU patients following Clinical Research protocol No. 99124006. The hypothesis on zero value of differences between invasive and non-invasive absolute ICP measurements under comparison was accepted after analysis of statistically significant clinical data of this study.

- 2.0. Approved statement of work: non-invasive ICP / volume real time monitoring.
- 2.5. Perform clinical evaluation of the prototype and the clinical study.

Accomplishment: the prototype has been evaluated in ICU. Clinical study of invasive and non-invasive slow blood volume wave and cerebrovascular autoregulation monitoring has been performed in ICU. 87 hours of simultaneous invasive and non-invasive monitoring have been performed on 13 ICU patients following Clinical Research protocol No. 99124006. The hypothesis on the coincidence between invasive and non-invasive monitoring data under comparison was accepted after analysis of statistically significant clinical data of this study.

Resume: All the approved statements of the work for the second year of this study have been successfully accomplished.

4. REPORTABLE OUTCOMES

The key research accomplishments were orally presented by Dr. A. Ragauskas at the conferences ATACCC 2001 (Fort Walton Beach, September, 2001) and ATACCC 2002 (Fort Sant Pete Beach, September, 2002). The abstracts of presentations are attached as an Appendix D to this report.

5. CONCLUSIONS

- 1. The clinical results of this study show that the prototype two-depth TCD device for absolute ICP measurement can be used in ICU environment. Our clinical study (57 measurements, 10 ICU patients with traumatic brain injuries) of the absolute ICP measurement below and above the critical level of ICP = 20.0 25.0 mmHg applying PI as a balance indicator shows that the systematic error of non-invasive absolute ICP meter is negligible and that is the only meter which do not need the individual calibration of the system "individual patient non-invasive ICP meter".
- 2. The hypothesis on zero value of differences between invasive and non-invasive absolute ICP measurements under comparison was accepted after analysis of statistically significant clinical data of this study.
- 3. A prototype time-of-flight device for cerebrovascular autoregulation state non-invasive monitoring has been designed and successfully tested in ICU following Clinical Research Protocol No. 9912 4006, AIBS No. 990135, HSSRB Log No. A 9676. 87 hours of simultaneous invasive and non-invasive ICP slow wave monitoring sessions were performed in ICU on patients with traumatic brain injuries. 53 one hour sessions of cerebrovascular autoregulation continuous monitoring were performed on ICU patients. Simultaneous invasive and non-invasive recording of slow ICP and slow intracranial parenchymal blood volume waves show a high correlation between invasively and non-invasively measured slow waves. The achieved highest correlation values were $R_{\text{C/V}} = 0.92 \dots 0.94$ during one-hour continuous monitoring session.
- 4. In order to obtain correlation coefficient between invasively and non-invasively recorded slow ICP and slow cerebral blood volume waves better than $r \ge 0.9$, it is necessary to perform the monitoring when the amplitude of ICP B waves is more than 3.0 mmHg (Fig. 11). The standard deviation of the correlation coefficient r is also minimal in this case (Fig. 12). The same conclusion about the acceptable amplitude of permanent or interminent ICP B waves follows from Fig. 14 concerning the standard deviation of the difference between invasively and non-invasively measured cerebrovascular autoregulation state indices. It follows from Fig. 16 that the acceptable ABP slow wave amplitude is more than 5.0 mmHg. It has been shown experimentally (Fig. 17, Fig. 18) that the difference between invasively and non-invasively measured CA indices expressed by the standard deviation σ (Fig. 18) decreases significantly when the autoregulation state has a tendency to be impaired ($r \to +1.0$) or to be intact ($r \to -1.0$). In both clinically important cases the random error values expressed by σ are not significant in the clinical practice. The systematic error Δ (Fig. 17, Fig. 19) is also not important in the clinical practice.
- 5. Statistically significant estimation (13 patients, 87 hours of continuous invasive and non-invasive monitoring) shows that the hypothesis of the coincidence of invasively and non-invasively measured ICP and IBV slow wave data is accepted (π >0.95). Statistically estimated (Bland Altman) difference between invasively and non-invasively recorded intracranial slow waves (SD=0.089, p=4.5x10⁻⁷) and the difference between invasively and non-invasively recorded cerebral autoregulation indexes (SD=0.05, p=1.1x10⁻⁶) is small enough and such differences are not clinically important.
- 6. In this clinical study the statistically significant evidences were obtained at the first time that ultrasonographic time-of-flight technology "Vittamed" could be applied for non-invasive continuous cerebrovascular autoregulation monitoring.
- 7. All the approved statements of the work for the second final year of this study have been successfully accomplished.

6. REFERENCES


- 1. D. Teres, R. Brown, and S. Lemshaw, "Predicting mortality of intensive care unit patients: the importance of coma," Crit. Care Med., vol. 10, pp. 86-95, 1982.
- 2. D. Levy, "Prognosis in nontraumatic coma," Ann. Int. Med., vol. 94, pp. 293-301, 1981.
- 3. P.Wolf, "An overview of the epidemiology of stroke," Stroke, vol. 21, pp. 4-6, 1990.
- 4. R. Burger, G. H. Vince, J. Meixensberger, K. Roosen. "Hypothermia influences time course of intracranial pressure, brain temperature, EEG and microcirculation during ischemia-reperfusion", Neurological Research, vol. 20, Suppl. 1, pp. S52-S60, 1998.
- 5. Ragauskas A., Daubaris G. A method and apparatus for non-invasively deriving and indicating of dynamic characteristics of the human and animal intracranial media // US Patent 5388583, 1995; Int. Patent Application PCT/IB94/00293, Intern. Publication WO95/06435, 1995; European Patent 0717606, 1999.
- 6. Piper I, "Intracranial pressure and elastance": In Head Injury. Ed. PL Reilly and R. Bullock, Chapman & Hall, London, 1997, pp. 101-120.
- 7. Miller JD, et al, "ICP monitoring: Indications and techniques", In: Narayan, RK: Neurotrauma, pp. 429-444, 1996,
- 8. J.D. Pickard, M. Czosnyka, "Management of raised intracranial pressure," Journal of Neurol Neurosurg Psychiatry, 56, pp 845-58, 1993.
- 9. H Kushiwaki et al,"Human dural thickness measured by ultrasonographic method: reflection of intracranial pressure," Journal Ultrasound Med, 16:11, pp. 725-30, 1997.
- 10. M.S. Salman, "Can intracranial pressure be measured non-invasively", The Lancet, 350:8, pp. 1367, 1997.
- 11. T. Ueno, R. Ballard et al, "Non-invasive measurement of intracranial pressure pulsation using ultrasound", Aviation Space and Environmental Medicine, 68:7, pp. 646, 1997.
- 12. N.L. Johnson, F.C. Leone. Statistics and Experimental Design in Engineering and Physical Sciences. John Wiley & Sons, 1977.
- 13. B.R. Kirkwood. Essentials of Medical Statistics. Blackwell Science Ltd, 1988.
- 14. US Patents No. No. 5 720 290, 5 840 018, 5 919 144, 5 993 398, 6 117 089, 6 150 941, 6 179 773, 6 231 509, 6 328 694, 6 364 849, 6 371 916, 6 375 607, 6 387 051, 6 422 990, 6 086 533, 6 231 509, 6 309 354.17
- 15. Czosnyka M, Pickard J, Whitehouse H, Piechnik S (1992). The hyperaemic response to a transient reduction in cerebral perfusion pressure. Acta Neurochir 115, 90-97.
- 16. Czosnika M, Smielewski P, Kirkpatrick P, Menon DK, Pickard JD (1996). Monitoring of cerebral autoregulation in head-injured patients. Stroke 27, 1829-1834.
- 17. Czosnika M, Smielewski P, Kirkpatrick P, Laing RJ, Menon D, Pickard JD (1997). Continuous assessment of the cerebral vasomotor reactivity in head injury. Neurosurgery 41, 11-19 (also private communication with Dr M Czosnyka).
- 18. Lemaire JJ, Boire JY, Chazal J, Irthum B (1994). A computer software for frequential analysis of slow intracranial pressure waves. Comput Methods Programs Biomed, 42, 1-14.
- 19. Lemaire JJ, Irthum B, Chazal J, Boire JY (1994). Statistical analysis of ICP and frequential analysis of slow waves during the course of subarachnoid haemorrhage following arterial aneurysm rupture: effects of vasospasm. ICP IX. Eds. Nagai H, Kamiya K, Ishii S. Springer-Verlag Berlin Heidelberg New York London Paris Tokyo Hong Kong Barcelona Budapest. 184-188.
- 20. Lemaire JJ, Chazal J, Gutknecht JL, Picard P, Irthum B, Boire JY (1994). Effects of acute compliance fluctuation on slow ICP waves: frequential aspects. ICP IX. Eds. Nagai H, Kamiya K, Ishii S. Springer-Verlag Berlin Heidelberg New York London Paris Tokyo Hong Kong Barcelona Budapest. 498-501.
- 21. Lemaire JJ, Burlat JF, Khalil T, Chabane A, Irthum B, Chazal J (1998). Computer software for frequential monitoring of intracranial pressure (and related signals) slow waves. Intracranial Pressure and Neuromonitoring brain Injury. Eds. Marmarou A, Bullock R,

- Avezaat C, Baethmann A, Becker D, Brock M, Hoff J, Nagai H, Reulen HJ, Teasdale G. Acta Neurochirugica [suppl] 71: 388.
- 22. Lemaire JJ, Khalil T, Cervenansky F, Boire JY, Sinardet D, Schmidt E, Fischer-Lokou D, Irthum B, Chazal J, Bonnard-Gougeon M (1998). Nouvelle méthode d'étude clinique de la vasomotricité cérébrale: approche de l'autorégulation dynamique ?Abstract XXèmes journées de l'Association de Neuro-anesthésie réanimation de langue Française. Paris, Sorbonne 19-20 novembre 1998 (also private communication with Prof. JJ Lemaire).
- 23. Ursino M, Giammarco PD (1991). A mathematical model of the relationship between cerebral blood volume and intracranial pressure changes: the generation of plateau waves. Ann Biomedical Engineer 19, 15-42 (also private communication with Prof. M Ursino).
- 24. Sahuquillo J, Amoros S, Santos S, Poca MA, Valenzuela H, Baguena M, Garnacho A. False autoregulation (pseudoregulation) in patients with severe head injury. Its importance in CPP management. Acta Neurochir (2000) [Suppl] 76: 485-490.
- 25. Czosnyka M., Smielewski P., Piechnik S., Steiner L. A., Pickard J. D. and Chir M. Cerebral autoregulation following head injury // J. Neurosurg., vol. 95, pp. 756-763, Nov. 2001.
- 26. Czosnyka M., Smielewski P., Piechnik S. and Pickard J. D. Clinical significance of cerebral autoregulation // Acta Neurochir., suppl. 81, pp. S117-S119, June 2002.
- 27. Czosnyka M., Pickard J., Whitehouse H. and Piechnik S. The hyperaemic response to a transient reduction in cerebral perfusion pressure // Acta Neurochir., vol. 115, pp. 90-97, 1992.
- 28. Czosnyka M., Smielewski P., Kirkpatrick P., Menon D. K. and Pickard J. D. Monitoring of cerebral autoregulation in head-injured patients // Stroke, vol. 27, pp. 1829-1834, 1996.
- 29. Czosnyka M., Smielewski P., Kirkpatrick P., Laing R. J., Menon D. K. and Pickard J. D. Continuous assessment of the cerebral vasomotor reactivity in head injury // Neurosurg., vol. 41, pp. 11-19, 1997.


APPENDIXES

APPENDIX A


CLINICAL RESULTS OF NON-INVASIVE ABSOLUTE INTRACRANIAL PRESSURE MEASUREMENT



Trial No. 1. Invasive ICP=8.5mmHg, non-invasive ICP=11.5mmHg




Trial No. 2. Invasive ICP=16mmHg, non-invasive ICP=16mmHg




Trial No. 3 Invasive ICP=14mmHg, non-invasive ICP=18mmHg

Patient "sl", file No.4 3 2.8 Averaged PI d=54mm 2.6 d=40mm Expon. (d=40mm) 2.4 Expon. (d=54mm) 2.2 2 0 5 10 15 20 25 Pe, mmHg

Trial No. 4 Invasive ICP=6mmHg, non-invasive ICP=6mmHg




Trial No. 5 Invasive ICP=8mmHg, non-invasive ICP=19mmHg




Trial No. 6 Invasive ICP=12mmHg, non-invasive ICP=14.5mmHg

Patient "dj", file No. 3 1.4 1.3 d=54mm **Averaged PI** 1.2 d=40mm 1.1 Expon. (d=40mm) 1 Expon. (d=54mm) 0.9 8.0 0 5 10 15 20 25 Pe, mmHg

Trial No. 7 Invasive ICP=14mmHg, non-invasive ICP=12mmHg




Trial No. 8 Invasive ICP=16mmHg, non-invasive ICP=16.5mmHg




Trial No. 9 Invasive ICP=10mmHg, non-invasive ICP=6mmHg

Patient "dj", file No.6 2.2 2 **Averaged PI** d=58mm 1.8 d=44mm 1.6 Expon. (d=58mm) 1.4 Expon. (d=44mm) 1.2 1 0 5 10 15 20 25 Pe, mmHg


Trial No. 10 Invasive ICP=5mmHg, non-invasive ICP=16mmHg




Trial No. 11 Invasive ICP=8mmHg, non-invasive ICP=19.5mmHg




Trial No. 12 Invasive ICP=10mmHg, non-invasive ICP=11.5mmHg



Trial No. 13 Invasive ICP=6mmHg, non-invasive ICP=13mmHg




Trial No. 14 Invasive ICP=4mmHg, non-invasive ICP=2mmHg




Trial No. 15 Invasive ICP=6mmHg, non-invasive ICP=3mmHg

Patient "od", file No.1 1.6 1.4 **Averaged PI** d=56mm 1.2 d=44mm Expon. (d=44mm) 1 Expon. (d=56mm) 8.0 0.6 0 5 10 15 20 25 30 35 40 45 50 Pe, mmHg

Trial No. 16 Invasive ICP=24mmHg, non-invasive ICP=34mmHg




Trial No. 17 Invasive ICP=20mmHg, non-invasive ICP=6mmHg




Trial No. 18 Invasive ICP=18mmHg, non-invasive ICP=17mmHg

Trial No. 19 Invasive ICP=16mmHg, non-invasive ICP=9mmHg




Trial No. 20 Invasive ICP=14mmHg, non-invasive ICP=15mmHg




Trial No. 21 Invasive ICP=11mmHg, non-invasive ICP=8mmHg

Patient "ri", file No.2 0.95 Averaged PI d=56mm 0.9 d=42mm 0.85 Expon. (d=56mm) 8.0 Expon. (d=42mm) 0.75 0.7 5 20 25 0 10 15 Pe, mmHg

Trial No. 22 Invasive ICP=13mmHg, non-invasive ICP=14mmHg




Trial No. 23 Invasive ICP=15mmHg, non-invasive ICP=8mmHg




Trial No. 24 Invasive ICP=8mmHg, non-invasive ICP=2mmHg

Patient "ri", file No.5 1.6 1.4 Averaged PI d=56mm 1.2 d=42mm Expon. (d=42mm) Expon. (d=56mm) 8.0 0.6 5 0 10 15 20 35 25 30 Pe, mmHg

Trial No. 25 Invasive ICP=12mmHg, non-invasive ICP=19mmHg




Trial No. 26 Invasive ICP=7mmHg, non-invasive ICP=5mmHg




Trial No. 27 Invasive ICP=9mmHg, non-invasive ICP=13mmHg

Patient "zp", file No.1 1.6 1.4 **Averaged PI** d=56mm 1.2 d=42mm Expon. (d=56mm) Expon. (d=42mm) 0.8 0.6 5 15 20 25 30 35 40 0 10 Pe, mmHg

Trial No. 28 Invasive ICP=15mmHg, non-invasive ICP=12mmHg




Trial No. 29 Invasive ICP=10mmHg, non-invasive ICP=3mmHg




Trial No. 30 Invasive ICP=12mmHg, non-invasive ICP=6mmHg

Patient "zp", file No.4 0.95 0.9 **Averaged PI** d=56mm 0.85 d=44mm 8.0 Expon. (d=56mm) 0.75 Expon. (d=44mm) 0.7 0.65 0.6 5 10 0 15 20 Pe, mmHg

Trial No. 31 Invasive ICP=5mmHg, non-invasive ICP=5mmHg




Trial No. 32 Invasive ICP=8mmHg, non-invasive ICP=0.5mmHg




Trial No. 33 Invasive ICP=11mmHg, non-invasive ICP=1mmHg

Patient "zp", file No.7 0.46 0.45 Averaged PI d≈56mm 0.44 d=44mm 0.43 Expon. (d=56mm) 0.42 | Expon. (d=44mm) 0.41 0.4 30 0 5 15 20 25 10 Pe, mmHg

Trial No. 34 Invasive ICP=7mmHg, non-invasive ICP=11mmHg




Trial No. 35 Invasive ICP=9mmHg, non-invasive ICP=12mmHg




Trial No. 36 Invasive ICP=5mmHg, non-invasive ICP=3mmHg

Patient "zp", file No.10 0.95 0.9 **Averaged** 0.85 0.75 0.7 d=56mm d=44mm Expon. (d=44mm) Expon. (d=56mm) 0.65 0.6 0 5 10 15 20 25 30 35 40 Pe, mmHg

Trial No. 37 Invasive ICP=24mmHg, non-invasive ICP=14mmHg




Trial No. 38 Invasive ICP=26mmHg, non-invasive ICP=32mmHg




Trial No. 39 Invasive ICP=29mmHg, non-invasive ICP=27mmHg

Patient "gs", file No.1 0.9 **Averaged D** 0.85 0.8 0.75 d=56mm d=42mm Expon. (d=42mm) Expon. (d=56mm) 0.7 15 20 25 0 5 10 30 35 40 Pe, mmHg


Trial No. 40 Invasive ICP=14mmHg, non-invasive ICP=16mmHg




Trial No. 41 Invasive ICP=16mmHg, non-invasive ICP=19mmHg




Trial No. 42 Invasive ICP=18mmHg, non-invasive ICP=12mmHg




Trial No. 43 Invasive ICP=22mmHg, non-invasive ICP=31mmHg




Trial No. 44 Invasive ICP=24mmHg, non-invasive ICP=17mmHg




Trial No. 45 Invasive ICP=20mmHg, non-invasive ICP=15mmHg



Trial No. 46 Invasive ICP=23mHg, non-invasive ICP=10mHg




Trial No. 47 Invasive ICP=27mHg, non-invasive ICP=24mHg




Trial No. 48 Invasive ICP=30mHg, non-invasive ICP=26mHg

Patient "ed", file No.6 0.35 0.3 **Averaged PI** d=54mm 0.25 d=40mm Expon. (d=40mm) 0.2 Expon. (d=54mm) 0.15 0.1 25 40 15 20 30 35 10 Pe, mmHg

Trial No. 49 Invasive ICP=26mHg, non-invasive ICP=24mHg




Trial No. 50 Invasive ICP=21mHg, non-invasive ICP=22mHg




Trial No. 51 Invasive ICP=33mHg, non-invasive ICP=43mHg

Patient "al", file No.1 0.6 Averaged Property 0.55 0.5 0.45 d=56mm d=44mm Expon. (d=56mm) Expon. (d=44mm) 0.4 0 5 10 15 20 25 30 35 40 Pe, mmHg

Trial No. 52 Invasive ICP=18mmHg, non-invasive ICP=10mmHg




Trial No. 53 Invasive ICP=20mmHg, non-invasive ICP=20mmHg




Trial No. 54 Invasive ICP=24mmHg, non-invasive ICP=26mHg

Patient "al", file No.4 0.6 Averaged D 0.55 - 0.5 - 0.45 | d=56mm d=44mm Expon. (d=44mm) Expon. (d=56mm) 0.4 0 5 10 15 20 25 30 35 40 Pe, mmHg

Trial No. 55 Invasive ICP=22mmHg, non-invasive ICP=10mHg




Trial No. 56 Invasive ICP=19mmHg, non-invasive ICP=13mHg




Trial No. 57 Invasive ICP=16mmHg, non-invasive ICP=12mHg

APPENDIX B


CLINICAL RESULTS OF SIMULTANEOUS INVASIVE SLOW INTRACRANIAL PRESSURE AND NON-INVASIVE SLOW INTRACRANIAL BLOOD VOLUME WAVES MEASUREMENT




File: ab2&ab3. Correlation coefficient $r(ICP, \Delta C/C_0) = 0.9194$




File:ab4&5&6. Correlation coefficient $r(ICP, \Delta C/C_0) = 0.8313$



File: ab6-part2&ab8. Correlation coefficient r(ICP, Δ C/C₀) = 0.7803



File: ag4_19part2. Correlation coefficient r(ICP, $\Delta C/C_0$) = 0.5780



8 waves of relative ultrasound speed. waves fittering range 30-120 s. File: ag4-19(part3)

0.4

0.2

0.4


0.0.1

0.0.2

0.3

Time, h


File:ag4_19part3. Correlation coefficient r(ICP, $\Delta C/C_0$) = 0.6457




File: as1&as4. Correlation coefficient $r(ICP, \Delta C/C_0) = 0.6380$

ICP B waves. Waves filtering range 30-120 s. File: as10 0.6 0.4 0.2 d CP, mmHg 0.5 d CP. -0.4 0.5 Time, h 0.1 0.2 0.3 0.7 0.8 B waves of relative ultrasound speed. Waves filtering range 30-120 s. File: as10 0.4 ΔC/C₀, (x 10⁻⁵) 0.5 Time, h 0.1 0.2 0.3 0.6 0.7 0.8 0.9


File: as10. Correlation coefficient r(ICP, $\Delta C/C_0$)= 0.5701




File: as12. Correlation coefficient r(ICP, $\Delta C/C_0$)= 0.4421




File:as2&as9. Correlation coefficient $r(ICP, \Delta C/C_0) = 0.6560$




File: as3. Correlation coefficient r(ICP, $\Delta C/C_0$) = 0.7976







File: as4-2. Correlation coefficient r(ICP, $\Delta C/C_0$) = 0.6748




File: as7-1. Correlation coefficient r(ICP, $\Delta C/C_0$)= 0.5193







File: as 7-2. Correlation coefficient r(ICP, $\Delta C/C_0$)= 0.4548




File: as8-1. Correlation coefficient r(ICP, Δ C/C₀)= 0.7578







File: as8-2. Correlation coefficient r(ICP, $\Delta C/C_0$)= 0.7294




File: dj8. Correlation coefficient r(ICP, Δ C/C₀) = 0.8704




File: dj13_15. Correlation coefficient $r(ICP, \Delta C/C_0) = 0.8585$




File: dj23_24. Correlation coefficient r(ICP, $\Delta C/C_0$) = 0.8002




File: dj28_32&dj44part1. Correlation coefficient r(ICP, Δ C/C₀) = 0.9335




File: dj44part2&dj47_52. Correlation coefficient r(ICP, Δ C/C₀) = 0.7978




File: dj57&dj59. Correlation coefficient r(ICP, $\Delta C/C_0$) = 0.9276




File: dj76-80. Correlation coefficient $r(ICP, \Delta C/C_0) = 0.5059$




File: jr1-4_part1. Correlation coefficient r(ICP, $\Delta C/C_0$) = 0.8856




File: jr1-4_part2. Correlation coefficient r(ICP, $\Delta C/C_0$) = 0.9100




File: jr1-4_part3. Correlation coefficient r(ICP, Δ C/C₀) = 0.7521




File: jr5-6. Correlation coefficient r(ICP, $\Delta C/C_0$) = 0.8373




File: jr7part1. Correlation coefficient $r(ICP, \Delta C/C_0) = 0.6519$



File: jr8. Correlation coefficient r(ICP, $\Delta C/C_0$) = 0.6549




File: kv1. Correlation coefficient $r(ICP, \Delta C/C_0) = 0.7374$




File: kv2_6part1. Correlation coefficient r(ICP, Δ C/C₀) = 7343


File: kv2_6part2. Correlation coefficient $r(ICP, \Delta C/C_0) = 0.8761$




File: mm3_13part1. Correlation coefficient r(ICP, Δ C/C₀) = 0.7489




File: mm15_22. Correlation coefficient r(ICP, $\Delta C/C_0$) = 0.7566




File: mm55&mm59_1. Correlation coefficient r(ICP, $\Delta C/C_0$) = 0.6674




File: mm59_2. Correlation coefficient r(ICP, $\Delta C/C_0$) = 0.7088




File: mm57_1. Correlation coefficient r(ICP, $\Delta C/C_0$) = 0.5706




File: mm57_2. Correlation coefficient r(ICP, Δ C/C₀) = 0.6351




File: mm57_3. Correlation coefficient $r(ICP, \Delta C/C_0) = 0.6869$




File: mm57_5. Correlation coefficient r(ICP, $\Delta C/C_0$) = 0.6019




File: mm60_1. Correlation coefficient $r(ICP, \Delta C/C_0) = 0.7361$




File: mm60_2. Correlation coefficient r(ICP, $\Delta C/C_0$) = 0.7307




File: rm_1v. Correlation coefficient r(ICP, $\Delta C/C_0$) = 0.8695




File: rm 2v. Correlation coefficient r(ICP, $\Delta C/C_0$) = 0.8989




File: rm_3v. Correlation coefficient r(ICP, $\Delta C/C_0$) = 0.9339




File: rm_4v. Correlation coefficient r(ICP, $\Delta C/C_0$) = 0.9612




File: rm_g4g5g6. Correlation coefficient r(ICP, Δ C/C₀) = 0.8875




File: rm-v100. Correlation coefficient r(ICP, $\Delta C/C_0$) = 0.9788




File: rm-101&v105&v106. Correlation coefficient r(ICP, $\Delta C/C_0$) = 0.9042




File: rm-v107&v119&v14. Correlation coefficient r(ICP, $\Delta C/C_0$) = 0.8972



File: sl2-3. Correlation coefficient r(ICP, $\Delta C/C_0$) = 0.8834




File: sl7. Correlation coefficient $r(ICP, \Delta C/C_0) = 0.8716$




File: sl21_26part1. Correlation coefficient r(ICP, $\Delta C/C_0$) = 0.9671


File: sl21_26part2. Correlation coefficient r(ICP, Δ C/C₀) = 0.8483



File: sl28-33part1. Correlation coefficient r(ICP, $\Delta C/C_0$) = 0.8503



File: sl28-33part2. Correlation coefficient r(ICP, $\Delta C/C_0$) = 0.6477




File: sl41&48. Correlation coefficient $r(ICP, \Delta C/C_0) = 0.7322$

ECP B waves. Waves filtering range 30-120 s. File: vd11-26(part1)


2
1
2
3
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1

B waves of relative ultrasound speed. Waves filtering range 30-120 s. File: vd11-26(part1)


File: vd11_26part1. Correlation coefficient r(ICP, Δ C/C₀) = 0.9131




File: vd11_26part2. Correlation coefficient r(ICP, $\Delta C/C_0$) = 0.9000




File: vd11_26part3. Correlation coefficient r(ICP, Δ C/C₀) = 0.9490




File: vd27_44part1. Correlation coefficient r(ICP, Δ C/C₀) = 0.9262




File: vd27_44part2. Correlation coefficient r(ICP, Δ C/C₀) = 0.8592




File: vd27_44part3. Correlation coefficient r(ICP, Δ C/C₀) = 0.9039




File: vg4. Correlation coefficient r(ICP, Δ C/C₀) = 0.6413




File: vg7&vg10part1. Correlation coefficient r(ICP, $\Delta C/C_0$) = 0.8850




File: vg10part2&vg2. Correlation coefficient r(ICP, $\Delta C/C_0$) = 0.8814



File: vg12. Correlation coefficient r(ICP, $\Delta C/C_0$) = 0.9284




File: vg15&18. Correlation coefficient r(ICP, Δ C/C₀) = 0.6107




File: vg21part1. Correlation coefficient r(ICP, $\Delta C/C_0$) = 0.5719


File: vg21part2. Correlation coefficient r(ICP, Δ C/C₀) = 0.5411




File: vyb1_3. Correlation coefficient $r(ICP, \Delta C/C_0) = 0.8122$




File: vyb6. Correlation coefficient r(ICP, $\Delta C/C_0$) = 0.9573




File: vyb7. Correlation coefficient r(ICP, $\Delta C/C_0$) = 0.9535




File: vyb8. Correlation coefficient r(ICP, $\Delta C/C_0$) = 0.9666




File: vyb9_13. Correlation coefficient $r(ICP, \Delta C/C_0) = 0.8655$




File: vyb14&16. Correlation coefficient r(ICP, $\Delta C/C_0$) = 0.7701



File: vyb17_21. Correlation coefficient $r(ICP, \Delta C/C_0) = 0.9621$




File: vk1_3. Correlation coefficient r(ICP, Δ C/C₀) = 0.8131




File: vm4&vm21_23. Correlation coefficient r(ICP, $\Delta C/C_0$) = 0.6407

File: vm5_10. Correlation coefficient r(ICP, Δ C/C₀) = 0.6445




File: vm11. Correlation coefficient r(ICP, $\Delta C/C_0$) = 0.5178

File: vm12. Correlation coefficient r(ICP, $\Delta C/C_0$) = 0.6378




File: vm14_17part1. Correlation coefficient r(ICP, $\Delta C/C_0$) = 0.8442


File: vm14 17part2. Correlation coefficient r(ICP, $\Delta C/C_0$) = 0.8574




File: vm14_17part3. Correlation coefficient r(ICP, Δ C/C₀) = 0.8428



File: vm14_17part4. Correlation coefficient r(ICP, $\Delta C/C_0$) = 0.8334




File: vm14_17part5. Correlation coefficient r(ICP, Δ C/C₀) = 0.7881




File: vm20. Correlation coefficient r(ICP, $\Delta C/C_0$) = 0.8462

APPENDIX C


CLINICAL RESULTS OF SIMULTANEOUS INVASIVE AND NON-INVASIVE CEREBROVASCULAR AUTOREGULATION STATE MONITORING




Correlation coefficients r(ABP,ICP) and r(ABP, Δ C/C $_0$) monitoring. Interval of processing 120s. File: ab2,ab3




Statistical processing of r(ABP,ICP) and r(ABP, Δ C/C₀): m=703, mD=0.0097, S=0.1411, R=0.9333




 $\text{Correlation coefficients r(ABP,ICP) and r(ABP,\Delta C/C}_{o}) \text{ monitoring. Interval of processing 120s. File: ab4,ab5,ab6} \\$




Statistical processing of r(ABP,ICP) and r(ABP,ΔC/C₀): m=703, mD=-0.0175, S=0.1618, R=0.8790




 $\text{Correlation coefficients r(ABP,ICP) and r(ABP,\Delta C/C}_0) \text{ monitoring. Interval of processing 120s. File: ab6(part2), ab8} \\$




Statistical processing of r(ABP,ICP) and r(ABP, Δ C/C₀): m=703, mD=-0.0268, S=0.1232, R=0.9010




 $\label{eq:correlation} \text{Correlation coefficients r(ABP,ICP) and r(ABP,\Delta C/C}_0) \text{ monitoring. Interval of processing 120s. File: as 2, as 9}$




Statistical processing of r(ABP,ICP) and r(ABP,ΔC/C₀): m=700, mD=-0.0409, S=0.3069, R=0.6243




 $\label{eq:correlation} \textit{Correlation coefficients r(ABP,ICP) and r(ABP,\Delta C/C_0) monitoring. Interval of processing 120s. File: as 3 and 3 and$




Statistical processing of r(ABP,ICP) and r(ABP, Δ C/C₀): m=681, mD=-0.1451, S=0.1909, R=0.68057




Correlation coefficients r(ABP,ICP) and r(ABP, Δ C/C $_0$) monitoring. Interval of processing 120s. File: as4-2




Statistical processing of r(ABP,ICP) and r(ABP, Δ C/C₀): m=703, mD= -0.2203, S=0.2389, R=0.52748




Statistical processing of r(ABP,ICP) and r(ABP, Δ C/C₀): m=703, mD= 0.1680, S= 0.2339, R= 0.8134




Statistical processing of r(ABP,ICP) and r(ABP, Δ C/C₀): m=703, mD= -0.0847, S= 0.2325, R= 0.6796




Statistical processing of r(ABP,ICP) and r(ABP, Δ C/C₀): m=703, mD= -0.0474, S= 0.1899, R= 0.6365






Statistical processing of r(ABP,ICP) and r(ABP, Δ C/C₀): m=703, mD= -0.0793, S= 0.1680, R= 0.7393



Statistical processing of r(ABP,ICP) and r(ABP,ΔC/C₀): m=703, mD=0.1404, S=0.1191, R=0.9044



Statistical processing of r(ABP,ICP) and r(ABP,ΔC/C₀): m=703, mD=0.1488, S=0.2760, R=0.5239

0.5

Time, h

0.6

0.7

0.8


0.9

-0.4 -0.6 -0.8


0.1

0.2


0.3




Correlation coefficients r(ABP,ICP) and r(ABP, Δ C/C $_0$) monitoring. Interval of processing 120s. File: dj23-24




Statistical processing of r(ABP,ICP) and r(ABP,ΔC/C₀): m=703, mD=0.2504, S=0.1961, R=0.8465




 $Correlation\ coefficients\ r(ABP,ICP)\ and\ r(ABP,\Delta C/C_0)\ monitoring.\ Interval\ of\ processing\ 120s.\ File:\ dj28,dj32,dj44(1)$




Statistical processing of r(ABP,ICP) and r(ABP,\Delta C/C_0): m=703, mD=-0.0462, S=0.1445, R=0.9414




Correlation coefficients r(ABP,ICP) and r(ABP, Δ C/C_n) monitoring. Interval of processing 120s. File: dj44(2),dj47-52




Statistical processing of r(ABP,ICP) and r(ABP, Δ C/C₀): m=698, mD=-0.3114, S=0.1216, R=0.8806




 $\text{Correlation coefficients r(ABP,ICP) and r(ABP,\Delta C/C}_0) \text{ monitoring. Interval of processing 120s. File: dj57,dj59} \\$




Statistical processing of r(ABP,ICP) and r(ABP,ΔC/C₀): m=703, mD=-0.0560, S=0.2092, R=0.8743




 $\text{Correlation coefficients r(ABP,ICP) and r(ABP,\Delta C/C_0) monitoring. Interval of processing 120s. File: dj76,dj78,dj80 \\$




Statistical processing of r(ABP,ICP) and r(ABP,\Delta C/C₀): m=703, mD=-0.2139, S=0.1844, R=0.7936




 $Correlation\ coefficients\ r(ABP,ICP)\ and\ r(ABP,\Delta C/C_n)\ monitoring.\ Interval\ of\ processing\ 120s.\ File:\ jr1-4\ part1$




Statistical processing of r(ABP,ICP) and r(ABP,ΔC/C₀): m=703, mD=-0.1066, S=0.1095, R=0.8842




 $\text{Correlation coefficients r(ABP,ICP) and r(ABP,\Delta C/C}_0) \text{ monitoring. Interval of processing 120s. File: } \\ \text{jr1-4 part2}$




Statistical processing of r(ABP,ICP) and r(ABP,ΔC/C₀): m=703, mD=-0.1942, S=0.1655, R=0.9149





 $\text{Correlation coefficients r(ABP,ICP) and r(ABP,\Delta C/C}_0) \text{ monitoring. Interval of processing 120s. File: } \\ \text{jr1-4 part3}$




Statistical processing of r(ABP,ICP) and r(ABP, Δ C/C₀): m=635, mD=-0.0481, S=0.2845, R=0.7881









Statistical processing of r(ABP,ICP) and r(ABP, Δ C/C₀): m=639, mD=-0.0347, S=0.1330, R=0.9144




Correlation coefficients r(ABP,ICP) and r(ABP, Δ C/C $_0$) monitoring. Interval of processing 120s. File: jr7-1





Statistical processing of r(ABP,ICP) and r(ABP, Δ C/C₀): m=703, mD=-0.3873, S=0.2193, R=0.5988






Statistical processing of r(ABP,ICP) and r(ABP,ΔC/C₀): m=703, mD=-0.1050, S=0.2741, R=0.7933







Statistical processing of r(ABP,ICP) and r(ABP, Δ C/C₀): m=703, mD=-0.2228, S=0.3117, R=0.7074




 $\text{Correlation coefficients r(ABP,ICP) and r(ABP,\Delta C/C}_0) \text{ monitoring. Interval of processing 120s. File: kv2-6 (part1)} \\$




Statistical processing of r(ABP,ICP) and r(ABP,∆C/C₀): m=703, mD=-0.2577, S=0.3295, R=0.5645



 $\text{Correlation coefficients r(ABP,ICP) and r(ABP,\Delta C/C}_0) \text{ monitoring. Interval of processing 120s. File: kv2-6 (part2) } \\$




Statistical processing of r(ABP,ICP) and r(ABP, Δ C/C₀): m=687, mD=-0.1464, S=0.2072, R=0.6049




Correlation coefficients r(ABP,ICP) and r(ABP,AC/C₀) monitoring. Interval of processing 120s. File: mm3-13 0.8 0.6 0.4 0.2 0 -0.2-0.4 -0.6 r(ABP,ICP) r(ABP,ΔC/C₀) -0.8 0.5 Time, h 0.6 0.8 0.9 0.1 0.2 0.3 0.4 0.7 'o


Statistical processing of r(ABP,ICP) and r(ABP,ΔC/C₀): m=703, mD=0.0676, S=0.2644, R=0.7806




 $Correlation\ coefficients\ r(ABP,ICP)\ and\ r(ABP,\Delta C/C_0)\ monitoring.\ Interval\ of\ processing\ 120s.\ File:\ mm15-22$




Statistical processing of r(ABP,ICP) and r(ABP,ΔC/C₀): m=623, mD=0.0620, S=0.2415, R=0.7967




 $\label{eq:correlation} \text{Correlation coefficients } \textit{r}(\text{ABP,ICP}) \text{ and } \textit{r}(\text{ABP,\DeltaC/C}_0) \text{ monitoring. Interval of processing 120s. File: } \textit{sl2-3}$




Statistical processing of r(ABP,ICP) and r(ABP,ΔC/C₀): m=703, mD=0.156, S=0.1302, R=0.8124




 $\label{eq:correlation} \text{Correlation coefficients r(ABP,ICP) and r(ABP,\Delta C/C}_0) \text{ monitoring. Interval of processing 120s. File: sl21-26(part1)}$




Statistical processing of r(ABP,ICP) and r(ABP,ΔC/C₀): m=703, mD=-0.0604, S=0.0945, R=0.9706




 $Correlation\ coefficients\ r(ABP,ICP)\ and\ r(ABP,\Delta C/C_0)\ monitoring.\ Interval\ of\ processing\ 120s.\ File:\ sl28-34\ part1$




Statistical processing of r(ABP,ICP) and r(ABP,ΔC/C₀): m=703, mD=-0.0792, S=0.1564, R=0.5975




 $Correlation\ coefficients\ r(ABP,ICP)\ and\ r(ABP,\Delta C/C_0)\ monitoring.\ Interval\ of\ processing\ 120s.\ File:\ sl28-34\ part2$




Statistical processing of r(ABP,ICP) and r(ABP, Δ C/C₀): m=697, mD=-0.1268, S=0.02646, R=0.7174




Correlation coefficients r(ABP,ICP) and r(ABP, Δ C/C $_0$) monitoring. Interval of processing 120s. File: sl41,48




Statistical processing of r(ABP,ICP) and r(ABP, Δ C/C₀): m=703, mD=0.5204, S=0.2130, R=0.8618







Statistical processing of r(ABP,ICP) and r(ABP,ΔC/C₀): m=703, mD=-0.2493, S=0.2195, R=0.7674




 $Correlation\ coefficients\ r(ABP,ICP)\ and\ r(ABP,\Delta C/C_0)\ monitoring.\ Interval\ of\ processing\ 120s.\ Files:\ vg10(part2),vg2$




Statistical processing of r(ABP,ICP) and r(ABP, Δ C/C₀): m=703, mD=0.0400, S=0.2612, R=0.7057




 $\text{Correlation coefficients r(ABP,ICP) and r(ABP,\Delta C/C}_0) \text{ monitoring. Interval of processing 120s. File: } \\ \text{vg12}$




Statistical processing of r(ABP,ICP) and r(ABP, Δ C/C₀): m=703, mD=0.0180, S=0.1435, R=0.7428




Correlation coefficients r(ABP,ICP) and r(ABP, Δ C/C $_{n}$) monitoring. Interval of processing 120s. Files: vg15 -18




Statistical processing of r(ABP,ICP) and r(ABP, Δ C/C₀): m=703, mD=0.2259, S=0.2821, R=0.5355




Correlation coefficients r(ABP,ICP) and r(ABP, Δ C/C $_0$) monitoring. Interval of processing 120s. File: vyb7





Statistical processing of r(ABP,ICP) and r(ABP, Δ C/C₀): m=682, mD=0.0029, S=0.1433, R=0.8404







Statistical processing of r(ABP,ICP) and r(ABP, Δ C/C₀): m=702, mD=0.0081, S=0.0504, R=0.9932 Correlation coefficient r(ICP, Δ C/C₀). Interval of processing 120s. File: vyb9-13









Statistical processing of r(ABP,ICP) and r(ABP, Δ C/C₀): m=696, mD=-0.0966, S=0.2122, R=0.8652




 $\text{Correlation coefficients r(ABP,ICP) and r(ABP,\Delta C/C}_0) \text{ monitoring. Interval of processing 120s. File: } \text{ } \text{vyb14,16}$




Statistical processing of r(ABP,ICP) and r(ABP, Δ C/C₀): m=703, mD=-0.0808, S=0.0871, R=0.9521




 $\text{Correlation coefficients r(ABP,ICP) and r(ABP,\Delta C/C}_0) \text{ monitoring. Interval of processing 120s. File: } \text{ } \text{vyb17-21}$




Statistical processing of r(ABP,ICP) and r(ABP,ΔC/C₀): m=703, mD=0.0112, S=0.1271, R=0.9541




Correlation coefficients r(ABP,ICP) and r(ABP, Δ C/C $_0$) monitoring. Interval of processing 120s. File: vyb1-3




Statistical processing of r(ABP,ICP) and r(ABP, Δ C/C₀): m=703, mD=0.1469, S=0.2335, R=0.7649 Correlation coefficient r(ICP, Δ C/C₀). Interval of processing 120s. File: vyb6




 $Correlation\ coefficients\ r(ABP,ICP)\ and\ r(ABP,\Delta C/C_0)\ monitoring.\ Interval\ of\ processing\ 120s.\ File:\ vyb6$




Statistical processing of r(ABP,ICP) and r(ABP,ΔC/C₀): m=684, mD=0.0747, S=0.1281, R=0.9639




Correlation coefficients r(ABP,ICP) and $r(ABP,\Delta C/C_0)$ monitoring. Interval of processing 120s. File: vk1-3




Statistical processing of r(ABP,ICP) and r(ABP,ΔC/C₀): m=703, mD=-0.1468, S=0.1546, R=0.7954




 $\label{eq:correlation} \text{Correlation coefficients r(ABP,ICP) and r(ABP,\Delta C/C}_0) \text{ monitoring. Interval of processing 120s. File: } \\ \text{vm5-10}$




Statistical processing of r(ABP,ICP) and r(ABP,ΔC/C₀): m=703, mD=-0.2288, S=0.2500, R=0.6953




Correlation coefficients r(ABP,ICP) and r(ABP, $\Delta C/C_n$) monitoring. Interval of processing 120s. File: vm12-13




Statistical processing of r(ABP,ICP) and r(ABP, Δ C/C₀): m=692, mD=-0.2109, S=0.2332, R=0.7893




Correlation coefficients r(ABP,ICP) and r(ABP,\DC/C0) monitoring. Interval of processing 120s. File: vm14-19 (part1)




Statistical processing of r(ABP,ICP) and r(ABP, Δ C/C₀): m=703, mD=-0.00670, S=0.1897, R=0.8495




Correlation coefficients r(ABP,ICP) and r(ABP, Δ C/C $_0$) monitoring. Interval of processing 120s. File: vm14-19 (part2)




Statistical processing of r(ABP,ICP) and r(ABP, Δ C/C₀): m=703, mD=-0.2166, S=0.1136, R=0.9071




 $Correlation \ coefficients \ r(ABP,ICP) \ and \ r(ABP,\Delta C/C_0) \ monitoring. \ Interval \ of \ processing \ 120s. \ File: \ vm14-19 \ (part3)$




Statistical processing of r(ABP,ICP) and r(ABP, Δ C/C₀): m=703, mD=-0.2107, S=0.1627, R=0.8693




Correlation coefficients r(ABP,ICP) and r(ABP, $\Delta C/C_p$) monitoring. Interval of processing 120s. File: vm14-19 (part4)




Statistical processing of r(ABP,ICP) and r(ABP, Δ C/C₀): m=703, mD=-0.3641, S=0.1406, R=0.8157




 $Correlation\ coefficients\ r(ABP,ICP)\ and\ r(ABP,\Delta C/C_0)\ monitoring.\ Interval\ of\ processing\ 120s.\ File:\ vm14-19\ (part5)$



Statistical processing of r(ABP,ICP) and r(ABP, Δ C/C₀): m=703, mD=-0.2963, S=0.2215, R=0.8380





Statistical processing of r(ABP,ICP) and r(ABP, Δ C/C₀): m=703, mD=-0.1978, S=0.1910, R=0.8709

APPENDIX D

ATACCC 2001, Fort Walton Beach (ABSTRACT OF ORAL PRESENTATION)

A. RAGAUSKAS

NON-INVASIVE MEASUREMENT OF INTRACRANIAL PRESSURE (ICP)

Objective: New ultrasonographic non-invasive ICP / Volume monitoring and ICP absolute value measurement methods were proposed in our previous works [1,2]. The objective of this paper is to present our clinical results of the assessment of non-invasive technology for cerebrovascular autoregulation monitoring and non-invasive ICP absolute value measurement in the intensive care unit (ICU).

Methods: Slow intracranial wave and ABP slow wave correlation methodology was used for cerebrovascular autoregulation monitoring. Non-invasive cerebrovascular slow wave monitor (Vittamed) has been used together with invasive ICP and ABP slow wave monitors in the ICU. Also ultrasonographic absolute ICP meter (Vittamed) was applied for periodic non-invasive measurements of ICU patients with traumatic brain injuries. All measurements were performed following Clinical Research Protocol of DoD Agreement DAMD 17-00-2-0065.

The non-invasively recorded slow volumetric intracranial waves were compared with invasively recorded slow ICP waves. Also continuous monitoring of the correlation factor $R_{\rm I}$ between invasively recorded ICP and ABP slow waves was performed simultaneously with non-invasively recorded correlation factor $R_{\rm N}$ between volumetric slow waves and ABP slow waves. The accuracy of absolute ICP non-invasive measurement was evaluated comparing non-invasive ICP data with simultaneously invasively measured ICP values.

Results: It has been shown experimentally that the correlation factor between invasively and non-invasively recorded slow ICP waves is not less than 0.71...0.93 during one hour monitoring periods (15 one hour ICU monitoring periods were analyzed). It has been shown an excellent agreement between non-invasive and invasive cerebrovascular autoregulation monitoring data.

The preliminary results of non-invasive ICP measurement method clinical assessment show that this is only method for non-invasive ICP measurement without the problem of individual calibration of system "patient – non-invasive ICP meter".

Conclusion: In this ongoing study it is shown at the first time that non-invasive ultrasonographic time-of-flight technology could be applied for continuous cerebrovascular autoregulation monitoring. It is shown that non-invasive absolute ICP meter (Vittamed) is only non-invasive ICP meter, which does not need an individual calibration of system "patient – non-invasive ICP meter".

- 1. Cerebrovasc Dis 1999;9 (suppl.2):31 and 46, also 2000;10 (suppl.1):34.
- 2. US Patents 5, 388, 583 and 5, 951, 477.

ATACCC 2002, Fort Sant Pete Beach (ABSTRACT OF ORAL PRESENTATION)

A. RAGAUSKAS

COMPARATIVE CLINICAL STUDY OF INVASIVE AND NON-INVASIVE INTRACRANIAL PRESSURE MONITORING TECHNIQUES

Objective: New ultrasonographic non-invasive intracranial pressure (ICP) / intracranial blood volume (IBV) monitoring and ICP absolute value measurement methods were proposed in our previous works [1,2]. The objective of this paper is to present the results of the completed comparative clinical study of invasive and non-invasive technology for cerebrovascular autoregulation monitoring and also invasive and non-invasive ICP absolute value measurement

in the neurosurgical intensive care unit (ICU).

Methods: In order to obtain a required statistical power of conclusions the number of patients was determined 10 and the number of measurement cycles was determined N>52 for this study. We performed 87 sessions of one hour simultaneous ICP and IBV wave monitoring on 12 ICU patients with severe traumatic brain injuries. We also performed 53 sessions of one hour simultaneous invasive and non-invasive cerebrovascular autoregulation monitoring on 10 patients from the same group. Invasive and non-invasive absolute ICP measurements (N=54) also have been performed on 10 ICU patients.

Slow ICP wave and slow ABP wave correlation methodology was used for invasive cerebrovascular autoregulation monitoring. Non-invasive IBV slow wave monitor (Vittamed) has been used together with invasive ICP and ABP slow wave monitors for simultaneous monitoring in the ICU. Also ultrasonographic absolute ICP meter (Vittamed) was applied for periodic non-invasive measurements on ICU patients with traumatic brain injuries. All measurements were performed following Clinical Research Protocol No. 9912 4006 (HSRRB Log No. A-9676) of DoD Agreement DAMD 17-00-2-0065.

The non-invasively recorded slow IBV waves were compared with simultaneously invasively recorded slow ICP waves. Also continuous monitoring of the correlation factor R_I between invasively recorded ICP and ABP slow waves was performed simultaneously with non-invasively recorded correlation factor R_N between IBV and ABP slow waves.

Statistical analysis (Student's *t*-test, Bland Altman plot, correlation analysis, etc.) of invasively and non-invasively measured data has been performed in order to evaluate a coincidence of invasively and non-invasively measured results.

Results: It has been shown experimentally that the reliable short- or long-term continuous non-invasive cerebrovascular autoregulation monitoring (Vittamed) can be used under ICU conditions. Statistically significant estimation (12 patients) shows that the hypothesis of the coincidence of invasively and non-invasively measured ICP and IBV slow wave data is accepted (π >0.95). Statistically estimated (Bland Altman) difference between invasively and non-invasively recorded intracranial slow waves (SD=0.089, p=4.5x10⁻⁷) and the difference between invasively and non-invasively recorded cerebral autoregulation indexes (SD=0.05, p=1.1x10⁻⁶) is small enough and such differences are not clinically important.

Bland Altman plot of 52 invasive and non-invasive measurements (10 patients) of absolute ICP values shows that the proposed method of non-invasive absolute ICP measurement (Vittamed) is only the method which does not need an individual calibration of the system "patient – non-invasive ICP meter". A good agreement was obtained between experimental results and mathematical modeling results of non-invasive absolute ICP measurement.

Conclusion: In this completed clinical study the statistically significant evidences were obtained at the first time that ultrasonographic time-of-flight technology (Vittamed) could be applied for non-invasive continuous cerebrovascular autoregulation monitoring. It is also evident that non-invasive absolute ICP meter (Vittamed) is only non-invasive ICP meter which does not need an individual calibration of system "patient – non-invasive ICP meter".

- 1. Cerebrovasc Dis 1999;9 (S2):31 and 46, Cerebrovasc Dis 2000;10 (S1):34, Cerebrovasc Dis 2002;13 (S4):18 and 25.
- 2. US Patents No. 5, 388, 583, No. 5, 951, 477, No. 6, 387, 051.

DEPARTMENT OF THE ARMY



US ARMY MEDICAL RESEARCH AND MATERIEL COMMAND 504 SCOTT STREET FORT DETRICK, MARYLAND 21702-5012

REPLY TO ATTENTION OF:

MCMR-RMI-S (70-1y)

18 Apr 03

MEMORANDUM FOR Administrator, Defense Technical Information Center (DTIC-OCA), 8725 John J. Kingman Road, Fort Belvoir, VA 22060-6218

SUBJECT: Request Change in Distribution Statement

- 1. The U.S. Army Medical Research and Materiel Command has reexamined the need for the limitation assigned to technical reports written for this Command. Request the limited distribution statement for the enclosed accession numbers be changed to "Approved for public release; distribution unlimited." These reports should be released to the National Technical Information Service.
- 2. Point of contact for this request is Ms. Kristin Morrow at DSN 343-7327 or by e-mail at Kristin.Morrow@det.amedd.army.mil.

FOR THE COMMANDER:

Encl

PHYLIS M. RINEHART

Deputy Chief of Staff for Information Management

ADB285846 ADB255323 ADB246514 ADB233740 ADB286395

ADB275662

ADB285859

ADB272667

ADB259790